1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	Niclosamide for Patients with Mild to Moderate Disease
13	from Novel Coronavirus (COVID-19)
14	Principal Investigator: Harry Selker, MD
15	01202021
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	

35 Summary of Changes from Previous Version:

Affected	Summary of Revisions Made	Ra	tionale
Section(s)			
Protocol Title	Addition of asymptomatic patients	1.	FDA
			recommendation
Study Synopsis	Addition of Day 21 fecal specimen,	1.	FDA
	addition of asymptomatic		recommendation
	participants, addition of Wellforce	2.	Recruitment
	and Clinical Research Network		optimization
	(CRN) sites for recruitment.	3.	Decreased
	Study duration 2 months, study		numbers of daily
	completion 4 months		COVD positive
			patients
Section 3.0	The primary objective of this study	1.	Viral shedding
Objectives and	is to determine if a course of	1	endpoint
endpoints	treatment with niclosamide		
	improves respiratory viral clearance		
	compared to treatment with		
	placebo.		
Section 4.0	Reduction in fecal viral shedding as	1.	FDA
Study design	measured by fecal PCR on days, 3,		recommendation
	7, 10, 14. Day 21 fecal specimen		
	added.		
Section 4.3	Additional literature and	1.	FDA
Justification of	background added		recommendation
Dose			
Section 5.1	Physical assessment data removed.	1.	Virtual
Inclusion	No need for oxygen		recruitment
Criteria	supplementation added.		
5.2 Exclusion	Systemic treatments removed as	1.	FDA
Criteria	exclusion.		recommendation
5.3 Lifestyle	Advisement to avoid alcohol added	1.	FDA
considerations			recommendation
5.5 Strategies	1. Updates to include Wellforce	1.	Recruitment
for recruitment	and CRN sites		enhancement
and retention	2. Twenty-dollar (\$20) ClinCard	2.	Time and effort of
	payment at each specimen	1	participants for
	collection timepoint		specimen
	3. Update to recruitment with		collection
	community outreach, study		
	information distribution and		
	nurses script	1	

6.1.1. Study Intervention	Day 21 fecal specimen added Additional data on oropharyngeal specimen collection added	1.	FDA recommendation
6.2.2 Formulation, Appearance, Packaging and Labeling	Study drug specific information added as provided by Bayer Pharmaceuticals	1.	Updated as per IND
6.2.3 and 6.2.4 Product storage and preparation	Changed to blister packaging	1.	Updated as per IND
7.2 Participant discontinuation/ withdrawal from study	Revised	1.	FDA recommendation
8.1 Efficacy assessments	 Baseline and screening (Day 0) Record COVID symptoms, if symptomatic Record number of days since onset of symptoms, if symptomatic Follow-up Evaluation Collect temperature and oximetry data daily, with the caveat that if O2 goes below 92%, an addition oximeter reading should be taken 2 hours later. <u>ADDED</u>: If the follow- up O2 saturation remains below 92%, the participant will be referred to their Primary Care Physician (PCP) or to the local Emergency Department Collect fecal samples for viral shedding Day 21 added 	1.	FDA recommendation
	A 30-day follow-up call and AE		

	assessment for those patients who are hospitalized will be performed.		
8.3.7 Reporting of pregnancy	Additional information added re: pregnancy and breast feeding	1.	FDA recommendation
10.1.6 Safety Oversight	Independent Safety Monitor and stopping rules added	1.	FDA recommendation
4.1 Overall Study Design	Addition of affiliate site recruitment detail		1. Reliance affiliate
1.1 Study Synopsis	Primary endpoint change	1.	Primary Efficacy Endpoint: Respiratory viral clearance at Day 3.
1.2 Schedule of activities	Addition of +/1 1-day windows	1.	Increase options for participant study visits
4.1 Overall study design	Increase sample size to n=200	1.	The current positivity rate on Day 1 of ~40% results in ITT sample size of 200.
5.1 Exclusion Criteria	Add: History of receipt of COVID-19 vaccine	1.	Potential effect of vaccine on viral shedding
5.2 Strategies for Recruitment	Added: Newton Wellesley Hospital, Maine Medical Center and New England Quality Care Alliance (NEQCA)	1.	Agreed to distribute study brochures and posters

6.1 Study Intervention	Removed: Transport by courier service to the Tufts Medical Center	1.	No contact FedEx pickup/ delivery to CLIA certified lab
	Telemedicine Platform	2.	Doximity platform used
	Removed: Amwell		useu
	Added: A HIPPA compliant		
	telehealth platform; e.g., Doximity,		
	will be used to conduct remote study visits.		
	Added: COVID positive list		
	generated twice daily		
	generated times daily		
9.1 Statistical	Sample size calculation revision	1.	Sample size
Hypothesis	Sample size calculation revision		increase
0.2 Comple Size	Device d		1. Increase d
9.2 Sample Size Determination	Revised		sample size
		1.	Sample size
9.3 Populations	Modified Intention-to-Treat		increase
for analysis	Analysis Dataset modified		
	Doviced analysis of the primary	1.	Sample size
9.4 Statistical	Revised analysis of the primary endpoint		increase
Analysis			

37		Table of Contents	
38	STATEMEN	NT OF COMPLIANCE	1
39		DTOCOL SUMMARY	
40	1.1	Synopsis	1
41	SchemA	3	
42	1.2	Schedule of Activities (SoA)	3
43	2 INTE	RODUCTION	5
44	2.1	Study Rationale	5
45	2.2	Background	
46	2.3	Risk/Benefit Assessment	
47	2.3.1	Known Potential Risks	
48	2.3.2	Known Potential Benefits	
49	2.3.3	Assessment of Potential Risks and Benefits	
50		IECTIVES AND ENDPOINTS	
51		IDY DESIGN	
52	4.1	Overall Design	
53	4.2	Scientific Rationale for Study Design	
54	4.3	Justification for Dose	
55	4.4	End of Study Definition	
56		JDY POPULATIOn	
57	5.1	Inclusion Criteria	
58	5.2	Exclusion Criteria	
59	5.3	Lifestyle Considerations	
60	5.4	Screen Failures	
61	5.5	Strategies for Recruitment and Retention	
62 63	6 STU 6.1	JDY INTERVENTION	
63 64	6.1.1	Study Intervention(s) Administration Study Intervention Description	
65	6.1.2	Dosing and Administration	
66	6.2	Preparation/Handling/Storage/Accountability	
67	6.2.1	Acquisition and accountability	
67 68	6.2.1		
	6.2.2	Formulation, Appearance, Packaging, and Labeling	
69 70	6.2.3 6.2.4	Product Storage and Stability	
70		Preparation	
71 72	6.3	Measures to Minimize Bias: Randomization and Blinding	
72 72	6.4 6.5	Study Intervention Compliance	
73	6.5	Concomitant Therapy Rescue Medicine	
74 75	6.5.1		1/
75 76		IDY INTERVENTION DISCONTINUATION AND PARTICIPANT NUATION/WITHDRAWAI	17
77	7.1	Discontinuation of Study Intervention	
78	7.2	Participant Discontinuation/Withdrawal from the Study	
79	7.3	Lost to Follow-Up	
80		JDY ASSESSMENTS AND PROCEDURES	
81	8.1	Efficacy Assessments	
82	8.2	Safety and Other Assessments	
83	8.3	Adverse Events and Serious Adverse Events	

84	8.3.1	Classification of an Adverse Event	22
85	8.3.2	Time Period and Frequency for Event Assessment and Follow-Up	23
86	8.3.3	Adverse Event Reporting	23
87	8.3.4	Serious Adverse Event Reporting	23
88	8.3.5	Reporting Events to Participants	24
89	8.3.6	Events of Special Interest	24
90	8.3.7	Reporting of Pregnancy	24
91	8.4	Unanticipated Problems	24
92	8.4.1	Definition of Unanticipated Problems (UP):	24
93	8.4.2	Unanticipated Problem Reporting	24
94	8.4.3	Reporting Unanticipated Problems to Participants	
95	9 STAT	FISTICAL CONSIDERATIONS	25
96	9.1	Statistical Hypotheses	
97	9.2	Sample Size Determination	
98	9.3	Populations for Analyses	25
99	9.4	Statistical Analyses	
100	9.4.1	General Approach	
101	9.4.2	Analysis of the Secondary Endpoint(s)	27
102	9.4.3	Safety Analyses	
103	9.4.4	Baseline Descriptive Statistics	
104	9.4.5	Planned Interim Analyses	
105	9.4.6	Sub-Group Analyses	
106	9.4.7	Tabulation of Individual participant Data	
107	9.4.8	Exploratory Analyses	
108		PORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS	
109	10.1	Regulatory, Ethical, and Study Oversight Considerations	
110	10.1.1	Informed Consent Process	
111	10.1.2	Study Discontinuation and Closure	
112	10.1.3	Confidentiality and Privacy	
113	10.1.4	Future Use of Data	
114	10.1.5	Key Roles and Study Governance	
115	10.1.6	Safety Oversight	
116	10.1.7	Clinical Monitoring	
117	10.1.8	Quality Assurance and Quality Control	
118	10.1.9	Data Handling and Record Keeping	
119	10.1.10		
120	10.1.11	Publication and Data Sharing Policy	
121	10.1.12	,	
122	10.2	Additional Considerations	
123	10.3	Abbreviations	
124	10.4	Protocol Amendment History	
125	11 REFE	ERENCES	40
126			

STATEMENT OF COMPLIANCE 127

- 128 The trial will be carried out in accordance with International Conference on Harmonisation Good Clinical 129 Practice (ICH GCP) and the following:
- 130 131

United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812)

- 132 National Institutes of Health (NIH)-funded investigators and clinical trial site staff who are responsible 133
- 134 for the conduct, management, or oversight of NIH-funded clinical trials have completed Human Subjects
- 135 Protection and ICH GCP Training.
- 136

The protocol, informed consent form(s), recruitment materials, and all participant materials will be 137

- submitted to the Institutional Review Board (IRB) for review and approval. Approval of both the 138
- 139 protocol and the consent form must be obtained before any participant is enrolled. Any amendment to
- the protocol will require review and approval by the IRB before the changes are implemented to the 140
- 141 study. In addition, all changes to the consent form will be IRB-approved; a determination will be made
- regarding whether a new consent needs to be obtained from participants who provided consent, using a 142
- previously approved consent form. 143

144 1 **PROTOCOL SUMMARY**

SYNOPSIS 145 1.1

Title:

Niclosamide for Patients with Mild to Moderate Disease from Novel Coronavirus (COVID-19)


Study This study will evaluate the antihelmintic drug, niclosamide, as a potential **Description:** treatment for mild to moderate coronavirus disease 2019 (COVID-19). Niclosamide, which has potent antiviral activity against single-stranded RNA viruses including coronaviruses, was proposed as an antiviral during the SARS outbreak in 2002 and has activity including SARS-CoV-2 where it was found to inhibit SARS coronavirus, SARS-CoV, in in vitro studies and similarly structured RNA viruses (both *in vitro* and *in vivo*). We hypothesize that the antiviral activity of Niclosamide may be extended to COVID-19.

Objectives:

- Primary Objective: To evaluate the efficacy of niclosamide in shortening contagious period as determined by time to viral clearance.
- Secondary Objectives: To evaluate the efficacy of niclosamide in mitigating • clinical outcomes and shortening duration of symptoms resulting from COVID-

19 infection.

Endpoints:	 Primary Efficacy Endpoint: Respiratory viral clearance at Day 3. Secondary Efficacy Endpoints: Fecal viral clearance at Day 14. Reduction in viral shedding as measured by oropharyngeal swab on days 1, 3, 7, 10, 14 Reduction in fecal viral shedding as measured by fecal PCR on days 1, 3, 7, 10, 14, 21 Progression to severe COVID, as a composite endpoint defined as O2 saturation <92% on room air in two consecutive measurements at least 2 hours apart OR requirement of hospitalization OR need for artificial ventilation OR death. Time to resolution of fever
	Safety endpoint: incidence of Adverse Events (AEs)
Study Population:	Patients 18 years of age or older who are COVID-19 (SARS-CoV-2) positive by PCR who are asymptomatic or have mild to moderate symptoms of COVID infection.
Phase:	Phase II
Description of Sites/Facilities	Study participants will be recruited for participation from Tufts Medical Center, Wellforce and Clinical Research Network (CRN) sites.
Enrolling Participants:	Participants will be identified as those reporting to Tufts Medical Center, Wellforce and CRN sites for outpatient COVID-19 testing. Patients with SARS-CoV-2 positive test results will be provided the option to participate in our study. The Study Team will enroll and randomize patients into the study after the patient has a confirmed positive test result and meets all the inclusion and none of the exclusion criteria. Additional sites and/or social media may be used to enhance recruitment. The
	study will be listed at www.clinicaltrials.gov.
Description of Study Intervention:	Participants in the treatment arm will receive niclosamide 2 grams orally once daily for 7 days in addition to current standard of care treatment. Those in the control group will receive placebo by mouth in the same numbers of pills on day 1 and daily for 6 more days (total 7 days of treatment) in addition to current standard of care treatment. Fecal samples and oropharyngeal swab samples will be collected for viral shedding as measured by PCR on days 3, 7, 10, 14 and 21 (fecal sample only). A baseline fecal and oropharyngeal sample will be obtained on Day 1 prior to starting dosing of niclosamide/ placebo.



	Screen & Baseline Day 0	Treat Day 1 +/- 1 day	Treat Day 2 +/- 1 day	Treat Day 3 +/- 1 day	Treat Days 4-6 +/- 1 day	Post- Treatment Day 7 +/- 1 day	Post- Treatment Day 10 +/- 1 day	Post- Treatment Day 14 * +/- 1 day	30-day Safety Call +/ - 1 Day
Confirmed COVID-19 + test	x								
Medical/ Social History (Demographics)	x								
Inclusion/ Exclusion Criteria	X								
Informed Consent	X								
Assign Subject ID	X								
Randomize	X								
	Initiation	of Study							
Dose treatment group with 2g niclosamide or placebo		Х	х	x	x				
Provide sample collection packet, thermometer, and finger-tip pulse oximetry		x							
	Participa	nt reporting a	and sample c	ollection					
AE reporting		x	x	X	x	x	x	x	x
O2 & Temp reporting		X	X	X	X	X	X	X	x
Oropharyngeal & fecal sample		X (prior to		х		X	x	x	

collection	dosing)
152 153 154 155	* An additional AE assessment and fecal specimen will be collected at day 21
156	2 INTRODUCTION
157	
158	2.1 STUDY RATIONALE
159	The ongoing COVID-19 pandemic is an urgent public health crisis with few if any rapid and practical
160	solutions. The outbreak of COVID-19 has been declared to be a public health emergency of international
161	concern by the World Health Organization (WHO), and the development of effective therapies for fast-
162	spreading fatal COVID-19 is in an urgent need. Given the seriousness and time-sensitive nature of this
163	highly contagious virus, the medical and scientific communities must work quickly and efficiently to find
164	a feasible way to address this global emergency.
165	Niclosamide is an anthelminthic drug that has been widely used in humans to treat tapeworm infections
166	for several decades and is currently listed on the WHO List of Essential Medicines, the safest and most
167	effective medicines needed in a health system. There are no current proven treatments for COVID-19,
168	and significant efforts are going toward developing novel therapeutics that have not been assessed for
169	safety in humans. There are a number of existing drugs prescribed for other indications that have
170	demonstrated potent antiviral activity [1-3]. In a recent study, Niclosamide exhibited antiviral activity
171	against SARS-CoV-2, the strain responsible for the current COVID-19 pandemic [3]. That niclosamide has
172	already demonstrated efficacy in specifically inhibiting SARS-CoV-2 replication in vitro is incredibly
173	promising.
174	A recent study evaluated clinical samples from 73 hospitalized patients with SARS-CoV-2 infection. In 39
175	of those patients, their fecal samples tested positive for SARS-CoV-2 RNA, with 17 of those patients
176	remaining SARS-CoV-2-positive in feces after becoming negative in respiratory samples [29]. Taken
177	together, this suggests that both the commonly accepted route of infection through the respiratory
178	system as well as the GI tract are implicated in the pathogenesis of COVID-19-related disease
179	manifestations.
180	While severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2-infected patients most
181	commonly present with fever, tiredness and dry cough; a subset of these patients present with
182	gastrointestinal (GI) issues [2]. Importantly, a recent study found that fecal viral shedding continues
183	nearly 5 weeks after the last detection of SARS-CoV-2 RNA in respiratory samples, suggesting that the GI
184	tract serves as a viral reservoir and allows for prolonged COVID-19 infection and transmission [4]. Given
185	that SARS-CoV-2 is so highly contagious and can be easily spread by both respiratory droplets and fecal-
186	oral route [5], limiting its transmission is paramount to public health. These data suggest that there is a
187	critical need to develop practical COVID-19 intervention strategies to treat SARS-CoV-2 infection and to
188	prevent person-to-person transmission.

- 189 Repurposing reliable and effective drugs for COVID-19 therapy is not only a safer strategy but will also
- allow for more rapid introduction into clinical practice. For this reason, we propose to use the widely
- used antihelmintic drug, Niclosamide for treatment of COVID-19.

192 2.2 BACKGROUND

193 SARS-CoV-2 has been shown to invade human tissues via the angiotensin converting enzyme II receptor

194 (ACE2), which is highly expressed on cell types found in various tissues [30]. In a study to identify

195 potential routes of infection for the SARS-CoV virus corresponding to the outbreak in China in 2002, a

remarkable finding was the high surface expression of ACE2 protein on human lung alveolar epithelial

- cells and enterocytes, the simple columnar epithelial cells lining the inner surface of the small and largeintestines[30].
- 199 This is not the first time that this small molecule (niclosamide) has been proposed as a therapeutic for

this specific application. Shortly after the SARS outbreak in China in 2002-2003, niclosamide was tested

201 for its potential use as an antiviral medication. Perhaps somewhat surprisingly, niclosamide was found

to inhibit SARS coronavirus, SARS-CoV, in in vitro studies [14]. Later studies went on to evaluate its

203 potential in combating coronavirus in vivo [31]. Fortunately, the SARS outbreak subsided rather quickly,

and as a result, no future interventions were necessary.

- 205 Multiple studies have studied the antiviral capacity of niclosamide in treating other similarly structured
- pathogenic viruses. During the outbreak of the Zika virus (ZIKV), another positive-sense RNA-based virus

similar to the coronavirus family, Niclosamide was again identified as a potential antiviral therapeutic,

with ZIKV-inhibiting effects both in vitro [13] as well as in a humanized in vivo model of ZIKV-induced

209 microcephaly [5]. Upon reviewing the literature, we found that niclosamide was also able to inhibit

210 production of a variety of viral strains [4, 7, 8, 10-12, 15, 32], including adenovirus [10], dengue [4] and

chikungunya virus [11]. Its mechanism of action in this capacity is to increase the pH within acidic

endosomes of host cells, thereby inhibiting virus entry and release.

In addition to its antihelmintic and antiviral properties, niclosamide has also demonstrated anti-bacterial

214 [8, 33, 34], anti-inflammatory [16, 17] and anti-cancer activity [18, 19, 23, 33, 35-40]. Moreover,

niclosamide has also shown promise for treating respiratory illness [14, 18, 20-22] even functioning as a

bronchodilator in an in vivo mouse model of asthma [21, 22].

217 Niclosamide has demonstrated efficacy as a cancer therapeutic in both animal models [19, 36] as well as

human clinical trials [23, 35] which suggests that in addition to potentially being efficacious in this anti-

219 COVID-19 capacity, Niclosamide is also likely to induce few complications as it is tolerated well even in

- immunocompromised cancer patients.
- 221 In the current pandemic crisis, medical professionals are understandably focused more on stabilizing the
- very sick. However, if niclosamide could work in any way to halt or prevent infection in the less sick (or
- even in the uninfected), it would be monumental in terms of returning to normal life. Because the drug
- is inexpensive and has few if any side effects, taking Niclosamide prophylactically might help to prevent
- 225 COVID-19 spreading. Even if this treatment does not completely eradicate infection, niclosamide

- 01022021
- treatment may help to decrease viral load, thereby allowing the host immune system to better combat
- the disease.

228 2.3 RISK/BENEFIT ASSESSMENT

229 2.3.1 KNOWN POTENTIAL RISKS

230 Niclosamide has been used since mid of the 1960s as an antihelmintic drug which inhibits glucose

231 uptake, oxidative phosphorylation and anaerobic metabolism. Niclosamide has few side effects and is

known to be well tolerated even when applied over a long period [19]. Reported adverse effects of

233 Niclosamide are mild and infrequent. This may include GI disturbances, lightheadedness, malaise, and

- pruritus. Alcohol may enhance the absorption of niclosamide, increasing the risk of side effects and
 therefore should be avoided when taking this drug.
- Pregnancy and breastfeeding are not exclusion criteria. The FDA categorizes medications based on
- 237 safety for use during pregnancy. Five categories A, B, C, D, and X, are used to classify the possible risks

to an unborn baby when a medication is taken during pregnancy.

239

240 Niclosamide falls into category B:

- There are no well-done studies that have been done in humans with Niclosamide. But in animal
- studies, pregnant animals were given this medication, and the babies did not show any medical issuesrelated to this medication.
- Studies in women suggest that this medication poses minimal risk to the infant when used during
 breastfeeding.
- 246 2.3.2

2.3.2 KNOWN POTENTIAL BENEFITS

247

248 Niclosamide is an oral medication that has been used to treat tapeworm infestations since 1960[6]. It is 249 on the World Health Organization (WHO) List of Essential Medicines, the safest and most effective 250 medicines needed in a health system [6]. In addition to its originally prescribed use, Niclosamide has been repurposed for a variety of clinical applications. Niclosamide has demonstrated antiviral activity 251 252 both in vitro and in vivo on a variety of single stranded RNA-based viral strains [4, 5, 7-13] and even SARS-CoV, a previous strain of coronavirus associated with the SARS outbreak in China in 2002[14]. Even 253 254 more recently, Niclosamide was shown to inhibit SARS-CoV-2, the strain responsible for the current COVID-19 pandemic [3]. Its mechanism of action in this capacity is to increase the pH within acidic 255 256 endosomes of host cells, thereby inhibiting virus entry and release [4, 11, 15]. In addition to its 257 antihelmintic and antiviral properties, Niclosamide has also demonstrated anti-inflammatory activity [16, 17], and has shown promise for treating respiratory illness [18-20] even functioning as a 258 bronchodilator in an in vivo mouse model of asthma [21, 22]. Furthermore, that Niclosamide has been 259 260 utilized in a variety of human clinical trials to enhance chemotherapeutics in cancer treatment [19, 23-25] suggests that is likely to induce few complications as it is tolerated well even in 261 262 immunocompromised cancer patients. 263

264 2.3.3 ASSESSMENT OF POTENTIAL RISKS AND BENEFITS

	Selker PI 01022021
265	The primary goal is to maximize patient safety. To fulfill this goal, Tufts and the study team will take
266	every measure to reduce patient risk of COVID-19-related complications, which includes the following:
267	 Reduction of in-patient and outpatient face- to face visits to limit amount of exposure to
268	patient and related populations
269	 Use of a courier service to provide study materials and no pickup and delivery FedEx to obtain
270	patient samples required for this study
271	 Extensive patient screening prior to enrollment to ensure that all enrolled patients meet
272	inclusion/exclusion criteria; more specifically to avoid enrollment of COVID-19 patients already
273	severely ill due to this disease. A screening and enrollment log will be maintained.
274	There is no expectation of severe adverse outcomes or reactions due to a patient being treated with
275	niclosamide. Niclosamide is generally well tolerated and has been prescribed clinically for over 30 years.
276	Reported AEs in current use are mild and include nausea and diarrhea. All participants will be given
277	access to contact information of the Study Team, and any adverse reactions will be reported as required
278	by the protocol.
279	
280	3 OBJECTIVES AND ENDPOINTS
281	
282	The primary objective of this study is to determine if a course of treatment with niclosamide improves
283	respiratory viral clearance compared to treatment with placebo.
284	
285	Secondary objectives include comparing the viral shedding from fecal samples and severity of clinical
286	outcomes between treatment groups.
287	
288	Primary Efficacy Endpoint:
289 290	Respiratory viral clearance at Day 3.
290 291	Secondary Efficacy Endpoints:
292	Fecal viral clearance at Day 14.
293	 Reduction in viral shedding as measured by oropharyngeal swab on days, 3, 7, 10, 14
294	• Reduction in fecal viral shedding as measured by fecal PCR on days, 3, 7, 10, 14 and 21
295	• Progression to severe COVID, as a composite endpoint defined as O2 saturation <92% on room
296	air in two consecutive measurements at least 2 hours apart OR requirement of hospitalization
297	OR need for artificial ventilation OR death.
298	Time to resolution of fever
299	Safety endpoint: incidence of AEs
300	
301	4 STUDY DESIGN
302	4.1 OVERALL DESIGN
303	
304	This is a double-blinded randomized controlled trial of 200 adult outpatients with mild to moderate

symptoms of COVID-19 not requiring hospitalization. Participants will be identified as those reporting to

- Tufts Medical Center seeking COVID-19 testing. All patients will be provided the option to participate in
 our study pending a positive SARS-CoV-2 test result. The Study Team will enroll and randomize patients
 into the study after the patient has a confirmed positive test result and meets all the inclusion and none
 of the exclusion criteria.
- Participants in the treatment arm (n= 100) will receive niclosamide 2g orally daily for 7 days in addition
- to current standard of care treatment. Those in the control group (n=100) will receive placebo by
- mouth in the same numbers of pills on day 1 and daily for 6 more days (total 7 days of treatment) in
- 313 addition to current standard of care treatment.
- Laboratory PCR testing will be performed at Tufts Medical Center laboratory or other CLIA certified lab.
- 315 Study participants will be recruited for participation from Tufts Medical Center. Associated sites at
- 316 Newton-Wellesley Hospital, Melrose Wakefield and Lowell General Hospital as well as CRN sites will be
- included in recruitment and engaged as deemed necessary by the Study Team to ensure identification
- and reporting of maximum number of positive cases and prompt patient engagement/ enrollment.
- 319
- A study recruitment brochure will be distributed at the associated Wellforce and CRN sites. A study poster will be available for affiliated outpatient sites that perform COVID testing. Both will include a QR
- code for ease of accessing study information. In addition, nurses who provide results to patients (by
- 323 phone) who have tested positive at Tufts Medical Center outpatient will provide basic, scripted study
- 324 information to potential participants. This information will include contact information for the Study
- Team and has been submitted to the Tufts IRB. Participation at Wellforce and CRN sites will be limited
- to distribution of study brochures and display of posters and (on a site by site basis) provision of PHI
- 327 (name and contact phone number of potential participants who express interest in the study). This
- information will be provided to the Tufts Study Team via a secure, encrypted message. Revisions to the
- 329 study brochure or any recruitment material will be provided to the site contact by the Tufts Study Team.
- 330 No research activities will be conducted at the associated sites (e.g., informed consent, study visits, data
- collection, data entry, data analysis, etc.). All study activity will be conducted by the Tufts Study Team.
- 332 The Tufts Study Team will keep record of the site of origin for each enrolled study participant. This de-
- identified, aggregated recruitment data will be provided to each site as requested by the site.
- 334

A study recruitment brochure will be distributed in the community. A study poster will be available for affiliated outpatient sites that perform COVID testing. Both will include a QR code for ease of accessing study information. In addition, nurses who provide results to patients (by phone) who have tested positive will provide basic, scripted study information to potential participants. This information will

- include contact information for the Study Team and has been submitted to the Tufts IRB.
- 340

Potential participants will initially be identified as those reporting to Tufts Medical Center, Wellforce or
 CRN outpatient. The Study Team will enroll and randomize patients into the study after the patient has
 a confirmed positive test result and meets all the inclusion and none of the exclusion criteria.

- 344
- Participants who provide informed consent and meet all of the inclusion and none of the exclusion criteria will be randomized on Treatment Day 0 in a 1:1 ratio to either the Treatment Group or the

- Control Group, in accordance with a computer-generated schedule prepared by a biostatistician. The
 randomization schedule will be incorporated into the REDCap Electronic Data Capture (EDC) system.
 Randomization will then be performed by study personnel directly in the EDC system. Study personnel
 will be instructed not to randomize until participant has been confirmed to meet all inclusion/exclusion
 criteria on treatment day 0.
- 352

354

353 4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN

Randomized double-blind placebo control (RDBPC) studies provide the strongest possible evidence of
causation. Phase II trials are used to determine the efficacy and safety of an intervention in participants
with the disease for which a new intervention is proposed. Randomization in combination with blinding
helps to avoid possible bias in the selection of participants, their assignment to an intervention or
control, and the analysis of their response to the intervention.

360

361 4.3 JUSTIFICATION FOR DOSE

- The standard oral dosage of Niclosamide prescribed for Hymenolepis nana tapeworm infestation (e.g. adults—maximum of 2 grams/day for seven days) is clinically efficacious in this antiviral capacity. Based on previous antiviral studies of Niclosamide both in vitro and in vivo [5, 13, 14], the average required dosage to achieve antiviral activity is 1 uM, which corresponds to ~0.327 µg/ml. In a recent clinical trial to test efficacy of Niclosamide as an antimetastatic therapy [23, 24], clinicians found that upon oral intake, Niclosamide Cmax plasma level peaked to a median of 0.665 µg/ml (ranging from 0.429 to 0.848 µg/ml), suggesting that traditional oral drug delivery should be sufficient to inhibit SARS-CoV-2
- production. Repeated dosing is commonly used when treating an infection where viruses may (at the
- time of ingestion) be at various stages of attachment, invasion, and replication.
- 371 Importantly, human infections with SARS-CoV-2 have demonstrated two known reservoirs of the virus.
- 372 Viremia tends to be relatively uncommon, with viral replication largely occurring in the respiratory and
- 373 gastrointestinal systems [37, 38]. The few cases in which SAR-CoV-2 titers are detectable in plasma have
- been reported in those patients already progressed to severe disease requiring hospitalization [39].
- 375 Plasma levels are limited both by oral absorption, but also by high plasma protein binding. In Bayer
- 376 simulations Cmax levels reaching almost 1200 nmol/l, or 1.2 uM is predicted. There is 99% plasma
- protein binding. Though free drug concentrations may not exceed the IC50 in plasma, we do not
- 378 anticipate viral burden in the plasma to be a significant contributor to disease or spread of virus.
- 379 While we firmly believe that standard oral delivery of Niclosamide will be sufficient to achieve anti-
- 380 COVID-19 activity, it is important to address certain issues previously posed with regard to the
- 381 pharmacokinetics of this drug. The inaugural publication describing studies of Niclosamide in human
- subjects reported that upon a single oral dose of 2g carbonyl-¹⁴C-labeled Niclosamide, up to 25% of ¹⁴C-
- 383 activity was detected in urine while the remainder was eliminated in feces[31] suggesting that
- 384 Niclosamide may be preferentially sequestered in the GI tract. Other studies have also suggested a
- similar biodistribution of Niclosamide in the colon[34]. Oral delivery of Niclosamide in mice infected with
- 386 an epidemic strain of Clostridium difficile, inhibited disease pathogenesis by targeting host mechanisms

Protocol 00000605 01022021 Selker PI 387 to prevent pathogen entry into intestinal epithelia without disrupting the endogenous gut microbiota[34]. With increasing insights emerging into the critical role of GI involvement in COVID-19 388 severity and transmission, this potential sequestration of Niclosamide in the gut could likely be 389 390 beneficial for both treatment strategies as well as prevention of transmission. 391 The second major viral reservoir, the respiratory tract, may be a key site of activity for the niclosamide. Though lung tissue and epithelial lining fluid concentrations are not available, there is measurable 392 393 activity in the respiratory tract. In a transgenic mouse model of asthma, niclosamide treatment (13 mg/kg/day) reduced mucus production, bronchoconstriction, and inflammation of airway tissues. 394 Assuming the average human weighs approximately 62kg, our dosing strategy of 2g/day, is the 395 396 equivalent of approximately 32mg/kg/day, which is significantly higher and likely to have similar effects. 397 In addition, systemic delivery of niclosamide (20mg/kg) significantly enhanced efficacy of chemotherapeutic drugs in an in vivo mouse model of non-small cell lung cancer [40], further 398 399 demonstrating that niclosamide can specifically target the lung in vivo. END OF STUDY DEFINITION 4.4 400 401 402 A participant is considered to have completed the study if he or she has completed all phases of the study including the last visit or the last scheduled procedure shown in the Schedule of Activities, Section 403 404 1.2. 405 406 **Early Termination/Hospitalization** All participants have the right to withdraw from study participation at any time during the study. If, for 407 408 whatever reason, a participant withdraws from the study or is hospitalized for increased severity of 409 COVID symptoms or other cause, an *Early Termination Visit* will be performed as deemed feasible by the PI or physician Investigator. 410 411 Any AE, SAE or other medical condition or situation that occurs such that continued participation in the 412 study would not be in the best interest of the participant will result in early termination. 413 414 415 The following procedures will be performed at the *Early Termination Visit*: Assess for AEs 416 • Assess for complications following treatments 417 • Document all current medications, including medications over the counter and herbal 418 ٠ 419 medications 420 Perform clinical assessment (as deemed feasible if hospitalized) Evaluate for increased severity of COVID-19-related disease 421 • 422 423 If clinical evaluation is deemed not feasible due to patient condition, the Study Team will collect as much 424 of the *Early Termination Visit* data via the Electronic Medical Record as is available. 425

426 5 STUDY POPULATION

NIC for COVID

Version 8.0

NIC for COVID Protocol 00000605

	Selker PI 01022021
427	5.1 INCLUSION CRITERIA
428 429 430 431 432 433 434 435 435 436 437 438	 In order to be eligible to participate in this study, an individual must meet all the following criteria: SARS-CoV-2 infection confirmed by PCR ≤ 3 days before randomization Provision of informed consent Stated willingness to comply with all study procedures and availability for the duration of the study Male or female, over 18 years of age No need for oxygen supplementation No requirement for hospitalization at the time of enrollment Ability to take oral medication and be willing to adhere to the Niclosamide/placebo regimen
439	5.2 EXCLUSION CRITERIA
440 441 442 443 444 445 446 447 448 449 450 451	 An individual who meets any of the following criteria will be excluded from participation in this study: Known allergic reactions to components of the niclosamide Participation in another trial or use of any experimental treatment for COVID-19, including chloroquine, hydroxychloroquine, remdesivir, and lopinapir/ritonavir History of receipt of COVID-19 vaccine* Current hospitalization or requiring hospital admission at screening * If a participant is enrolled in the study and then subsequently has an appointment for the COVID-19 vaccine, they will remain on study and will be advised that they can keep their vaccine appointment. Vaccine administration will be noted and considered in the final data analysis.
452	5.3 LIFESTYLE CONSIDERATIONS
453 454 455 456 457	No special preparations or additional steps (for example, special diets, fasting, other medicines, laxatives, or enemas) are necessary before, during, or immediately after taking niclosamide. Participants are advised to avoid alcohol consumption during the study treatment period.
458	5.4 SCREEN FAILURES
459 460 461 462 463 464 465 466	Screen failures are defined as participants who consent to participate in the clinical trial but are not subsequently randomly assigned to the study intervention or entered in the study. A minimal set of screen failure information is required to ensure transparent reporting of screen failure participants, to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any SAE.
467	5.5 STRATEGIES FOR RECRUITMENT AND RETENTION

468	
469	Participants will be identified as those outpatients reporting to Tufts Medical Center, Wellforce or our
470	CRN sites seeking COVID-19 testing. Any asymptomatic patient and those with mild to moderate COVID-
471	19 symptoms not requiring hospital admission or supplemental oxygen, will be provided the option to
472	participate in our study once they have a reported positive SARS-CoV-2 test result. Lowell General, St.
473	Elizabeth's, Newton Wellesley Hospital, Maine Medical Center and New England Quality Care Alliance
474	(NEQCA) have agreed to distribute our study brochure at the time of testing at their drive thru testing
475	and ambulatory locations. These sites will also be displaying our study poster (with QR code) in the ED,
476	Primary Care clinics. Additional Wellforce and CRN sites may be used to enhance recruitment. Study
477	brochures and promotional material will be given to potential participants at each of the testing sites
478	including study team contact information. The study brochure will be given to the patient at the time of
479	COVID- 19 testing, by the testing site personnel. The participant will proactively contact the study team
480	if interested in participation following a positive COVID-19 test.
481	
482	The Study Team will enroll and randomize patients meeting the above criteria into the study after the
483	patient has a confirmed positive test result and meets all of the inclusion and none of the exclusion
484	criteria.
485	
486	Tufts Community Health Improvement Program will incorporate the distribution of study material
487	(brochure) with their general COVID-19 materials within the Chinatown community and residential
488	towers. The Tufts Medical Center (TMC) Symptom Clinic, staffed by TC registered nurses (RNs), will be
489	contacting patients who test positive by phone. The RN will give a brief (scripted) overview of the study
490	and contact information for the study team at the time of call to provide testing result.
491	,
492	Social media will be used to enhance recruitment. This study will be listed at www.clinicaltrials.gov.
493	, , , , , , , , , , , , , , , , , , , ,
494	Participants will be offered twenty dollars (\$20) for time and effort (via ClinCard) at each specimen
495	collection timepoint (Days 1, 3, 7, 10, 14 and 21).
496	
497	All research activity including Informed Consent will be performed by Tufts Medical Center employees.
498	,
499	6 STUDY INTERVENTION
500	6.1 STUDY INTERVENTION(S) ADMINISTRATION
501	
502	6.1.1 STUDY INTERVENTION DESCRIPTION
503	
504	Informed Consent will be obtained, all the inclusion and none of the exclusion criteria are met.
505	
506	In addition to niclosamide or placebo treatments, all enrolled patients will be provided a home
507	thermometer as well as a fingertip probe pulse oximeter, with the specific instructions to monitor both
508	temperature at oxygen saturation at the time of daily oral administration of drug. The relatively low

- 01022021
- reported percentage of error for the finger probe supports that the finger probe is the modality of
- 510 choice to measure intermittent oxygen saturation in the outpatient setting.
- 511
- 512 Oropharyngeal and fecal swabs will be collected at days 1 (baseline), 3, 7, 10, and 14 of the study. An
- additional fecal specimen will be collected at day 21. In the case of oropharyngeal samples, care will be
- taken to ensure that sampling methods are consistent for each individual patient across all included
- 515 timepoints, to limit any bias due to potential differences in viral load.
- 516
- 517 Oropharyngeal collection is minimally invasive and can reliably be self-administered. Recent research
- testing SARS-CoV-2 detection, nasopharyngeal and oropharyngeal (saliva) samples from confirmed
- 519 SARS-CoV-2 found that oropharyngeal yielded greater detection sensitivity and consistency throughout
- 520 the course of infection. Less variability in self-sample collection was also found. This research
- 521 demonstrated that oropharyngeal samples are a viable and more sensitive alternative to
- nasopharyngeal swabs and can enable at-home self-administered sample collection for accurate SARS-
- 523 CoV-2 testing [41, 42].
- 524
- 525 The collection of oropharyngeal samples will be directly observed by a Study Team member via the
- telehealth platform. The participant will open the viral transport kit and swab the back of the throat and
- 527 tonsil area (avoiding mouth, teeth, and gums) and place to swab back into the vial. For fecal specimen,
- 528 the participant will swab feces from a plastic container (or wrap) placed on the toilet seat. Printed
- 529 instructions will be provided to each participant with detail on how to collect both the oropharyngeal
- and fecal specimens. These instructions will also be reviewed with the participant by a member of the
- 531 Study Team.
- 532
- 533 Once obtained, samples will be transported by no contact pickup and delivery FedEx service to the Tufts 534 Medical Center or CLIA- certified lab to prevent unnecessary hospital visits and to encourage compliance 535 given the self-quarantine status of enrolled patients.
- 536

537 Telemedicine Platform

- 538
- 539 A HIPPA compliant telehealth platform; e.g., Doximity, will be used to conduct remote study visits. 540
- 541 Twice daily a list of COVID-19 positive patients will be generated by the Tufts Medical Center lab and
- 542 provided to the Study Team via a secure Tufts email account. Upon receiving the COVID-19 positive test
- 543 notification, COVID-19 positive participants will be approached remotely by a study Investigator for
- remote (telephone) Informed Consent. Once consent is obtained, all the
- and none of the exclusion criteria are met, the study CRC will engage with the participant to enroll themin the telehealth platform and schedule the follow-up telehealth study appointments.
- 547
- 548 If the participant does not have a Smartphone, one will be provided to them along with the other study
- 549 materials. A prepaid USPS envelope with additional instructions will be provided to send the package
- 550 through the USPS for return. Participants will be guided thru the step-by-step telemedicine setup on
- their Smartphone by the study CRC. Scripted guidance will be provided to the study CRCs to ensure that

- instructions provided to participants are consistent. For example, included in the script, the study CRC
- will provide instruction in simple, easy to understand language such as, "I am going to take a minute and
- walk you through signing up for the app so you are ready on your visit date. "I've have actually gone
- ahead and scheduled the visit for you in the app". The app is navy blue, has a picture of a doctor with a
- *stethoscope and lighter blue heart".* Once set up, a reminder of the upcoming appointment will be sent
- to the participant via email and text message.
- 558

559 Once the participant "checks- in" for their study visit, the CRC, investigator, or Study Team member will 560 receive a notice that the participant is in the *Waiting Room*. A family member or other support person 561 of the participant's choice can be included in any/all visits via Facetime. More than one study team 562 member can also join the appointment as needed or desired with the *"Add Person"* Facetime 563 number/address. Once the study team enters the *Waiting Room*, a split screen clearly displays the 564 patient, support person and the study team member(s).

565 566 6.1.2 DOSING AND ADMINISTRATION

Participants eligible for the study will review and undergo informed consent at the time they receive
confirmation of positive SARS-CoV-2 test result. After obtaining consent, participants will be randomly
assigned on a 1:1 basis to receive:

570 571

572

573

574 575

- **Treatment Group blinded:** Will receive niclosamide 2g orally daily for 7 days in addition to current standard of care
 - **Control Group blinded:** Will receive placebo by mouth daily for 7 days in addition to current standard of care

Niclosamide may be taken on an empty stomach (either 1 hour before or 2 hours after a meal).
However, to prevent stomach upset, it is best taken after a light meal (for example, breakfast).
Participants will be advised to avoid alcohol consumption during study treatment period.

- 579
- 580

582

6.2

PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY

581 6.2.1 ACQUISITION AND ACCOUNTABILITY

In accordance with recent COVID-19 FDA Guidance, if scheduled visits at clinical sites are significantly
 impacted, certain IP, such as those that are typically distributed for self-administration, may be
 amenable to alternative secure delivery methods. As such:

- 586
- Niclosamide and placebo (Investigational Product, IP) will be stored in the Tufts Medical Center
 Investigational Pharmacy. Upon enrollment, the investigational pharmacy will package and dispense the
 IP to the patient, along with the sampling kit. The entire supply of study medication will be dispensed at
 one time. It will be delivered to the subject via courier service. Subjects will be asked to document
- 591 compliance with study protocol in a subject diary. If a subject does not use all the IP, the remainder
- shall be returned to the study investigators with the day 14 samples. The IP will then be returned to the
- 593 manufacturer or destroyed on site.

01022021 Selker PI 594 Investigational new drug application (IND) submitted under section 505(i) of the Federal Food, Drug, and 595 Cosmetic Act (FDCA) for Niclosamide chewable tablets, 500 mg has been approved: FDA IND # 151423. 596 597 598 Placebo manufacturer KABS Laboratories Inc. See Appendix A for manufacturing detail. 599 600 601 6.2.2 FORMULATION, APPEARANCE, PACKAGING, AND LABELING 602 Niclosamide will be provided as 500 mg chewable tablets. They are gray-yellow round tablets with FE 603 604 printed on one side and the "Bayer Cross" on the other side. The excipients include: corn starch, talc, sodium lauryl sulphate, povidone, vanillin, magnesium stearate, saccharin sodium. They will be 605 provided in blister packages for ease of use and enhanced stability. They will be labeled as "Niclosamide 606 OR Placebo," with adequate administration instructions prior to dispensing to subjects. 607 608 6.2.3 PRODUCT STORAGE AND STABILITY 609 610 Niclosamide and the placebo are oral tablets. They can be stored at room temperature, 25°C (77°F) with 611 612 excursions permitted to 15-30°C (59-86°F). They will be dispensed in blinded blister packaging. 613 6.2.4 PREPARATION 614 615 There will be no significant preparation. Both niclosamide and placebo tablets will be dispensed in blinded blister packages and labeled in accordance with state and federal regulation. 616 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING 617 6.3 618 Participants who sign informed consent and meet all inclusion and exclusion criteria will be randomized 619 620 on Treatment Day 0 in a 1:1 ratio to either the Treatment Group or the Control Group, in accordance with a computer-generated schedule prepared by a biostatistician. The randomization schedule will be 621 622 incorporated into the REDCap EDC system. Randomization will then be performed by study personnel directly in the EDC system. Study personnel will be instructed not to randomize until participant has 623 been confirmed to meet all inclusion/exclusion criteria on treatment day 0. 624 625 626 As all members of the Study Team will be blinded, Tufts Investigational Drug Services (IDS) will be 627 unblinded and will dispense both the Niclosamide and placebo. The study intervention (niclosamide) and placebo will be packaged and as indistinguishable as possible. 628 629 630 Refer to Section 9, Statistical Considerations for sample size calculations. 631 632 6.4 STUDY INTERVENTION COMPLIANCE 633 During the Baseline and Screening (Day 0), the Principal Investigator (PI) or a co-Investigator will review the study with the participant and obtain informed consent and Health Insurance Portability and 634

- Accountability Act of 1996 (HIPAA) authorization. A second member of Study Team (e.g., the study
- 636 Clinical research coordinator (CRC)) will serve as a witness to the informed consent. After the informed
- 637 consent is obtained, the participant will be assigned a unique enrollment number. The subject will then
- 638 be randomized to treatment in EDC and provided blinded treatment (either Niclosamide or placebo) and
- other study materials via courier.

640	On <i>Treatment Day</i> 1, a member of the Study Team or study CRC will review the dosing and schedule of
641	Niclosamide/ placebo.
642	 The patient will be instructed to record all doses in Study Drug Administration Diary
643	• During each telehealth visit, the study CRC or other Study Team member will review the diary
644	with the participant
645	The participant will be advised not to discard any study pill bottles
646	Baseline AEs, O2 saturation, temperature, oropharyngeal & fecal sample collection will be
647	obtained
648	
649	Refer to the Section 1.2, Schedule of Activities.
650	
651	6.5 CONCOMITANT THERAPY
652	
653	Concomitant therapies are any new or existing medications or therapy taken by the patient including:
654	• Drugs, including but not limited to, prescription, over the counter, birth control
655	pills/patches/hormonal devices, and homeopathic preparations
656	 Nondrug therapies, including but not limited to, thermal/laser/radiation procedures, vitamins,
657	herbal medicines/supplements.
658	herbar meanines, supplements.
659	During the Screening process, information on all concomitant therapies, medications, and procedures
660	will be recorded in the source documents and appropriate Case Report Form (CRF) along with the
661	diagnosis or reason for use. Once the patient receives the first dose of study drug, recording of
662	concomitant therapies will be limited to any new medication or modification of an existing medication
663	taken for treatment of an AE. These therapies will be recorded in the source documents and appropriate
664	CRF along with the diagnosis or reason for use. Those therapies used for the treatment of an adverse
665	event are to be linked to an AE and documentation of the AE must also be completed
666	
667 668	6.5.1 RESCUE MEDICINE The study site will not supply rescue medication.
669	The study site will not supply rescue medication.
670	7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT
671	DISCONTINUATION/WITHDRAWAL
672	7.1 DISCONTINUATION OF STUDY INTERVENTION
673	
674	This study may be temporarily suspended or prematurely terminated if there is enough reasonable
675	cause. Written notification, documenting the reason for study suspension or termination, will be

- provided by the suspending or terminating party to the study team, the Sponsor and the Institutional
- 677 Review Board (IRB), as appropriate. If the study is prematurely terminated or suspended, the study
- team will promptly inform the IRB and will provide the reason(s) for the termination or suspension.
- 679
- Discontinuation from niclosamide does not mean discontinuation from the study, and remaining study
 procedures should be completed as indicated by the study protocol. If a clinically significant finding is
 identified (including, but not limited to changes from baseline) after enrollment, the investigator or
- qualified designee will determine if any change in participant management is needed. Any new clinically
- relevant finding will be reported as an AE.
- 685

686 7.2 PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY

All participants are free to withdraw from participation at any time, for any reason, specified or 687 unspecified, and without prejudice. Reasonable attempts will be made by the Investigator to provide a 688 reason for participant withdrawals. The reason for the participant's withdrawal from the study will be 689 specified in the participant's source documents and the CRF. The study team will make every effort to 690 691 contact participants who are lost to follow-up. Attempts to contact such participants will be documented in the participant's records (e.g., times and dates of attempted telephone contact, receipt 692 693 for sending a registered letter, etc.). 694 A participant will be discontinued from the study for the following reasons only: 695 Participant withdrawal of consent 696 Lost to follow-up 697 ٠ Participant death 698 • Hospitalization for severe COVID- 19 symptoms 699 ٠ 700 The following procedures will be performed at the *Early Termination visit*: 701 Assess for AEs • 702 Assess for complications following treatments • 703 Document all current medications, including medications over the counter and herbal 704 medications Perform clinical assessment (as deemed feasible if hospitalized) 705 • Evaluate for increased severity of COVID-19-related disease 706 707 708 If clinical evaluation is deemed not feasible due to patient condition, the Study Team will collect as much Early Termination Visit data as possible from the Electronic Medical Record 709 710 The reason for participant discontinuation or withdrawal from the study will be recorded on the CRF. 711 712 713 7.3 LOST TO FOLLOW-UP

- A participant will be considered lost to follow-up if he or she fails to complete more than (2) scheduled
- telehealth visits and is unable to be contacted by the study staff.
- 717

The following actions must be taken if a participant fails to attend a required telehealth visit:

- The Study Team will attempt to contact the participant and reschedule the missed visit and
 counsel the participant on the importance of maintaining the assigned visit schedule and
 ascertain if the participant wishes to and/or should continue in the study.
- Before a participant is deemed lost to follow-up, the investigator or designee will make every
 effort to regain contact with the participant (where possible, 3 telephone calls and, if necessary,
 a certified letter to the participant's last known mailing address or local equivalent methods).
- 725 These contact attempts will be documented in the participant's medical record or study file.
 726 Should the participant continue to be unreachable, he or she will be considered to have
- withdrawn from the study with a primary reason of lost to follow-up.
- 728 729
- For participants considered lost to follow-up, the CRF will be completed up to the last contact with the participant.
- 730

731 8 STUDY ASSESSMENTS AND PROCEDURES

- 732 8.1 EFFICACY ASSESSMENTS
- The specific timing of procedures/evaluations to be done at each study visit are found in *Section 1.2, Schedule of Activities.* All assessment will be performed by the study investigators or a qualified
 member of the study team.
- 737

738 Baseline and Screening (Day 0)

- The following procedures will be performed at the Baseline/Screening visit:
- Review the study with the participant and obtain written informed consent and Health
 Insurance Portability and Accountability Act of 1996 (HIPAA) authorization
- Assign the participant a unique enrollment number
- Review and record medical history, surgical history, and medication history to determine
 eligibility based on inclusion/exclusion criteria
- Record smoking history
- Record demographics (age, race, ethnicity, gender)
- Document all current medications, including medications over the counter and herbal
 medications
- Record COVID symptoms, if symptomatic
- Record confirmation of positive SARS-CoV-2 test result
- Record number of days since onset of symptoms, if symptomatic
- 752 Randomization and Treatment (Day 0)
- Confirm patient meets all inclusion and none of the exclusion criteria
- Randomize subject to treatment in EDC

	Protocol 00000605 Selker PI 01022021	
755	• Provide blinded treatment (either niclosamide or placebo) and other study materials via courier	
756		
757	Follow-Up Evaluation	
758	Remote clinical follow-up will occur at the following time points: Days 1, 2, 3, 7, 10, 14, 21 and 30.	
759	The following procedures will be performed at all follow-up visits, expected to be done by tele-medical	
760	methods, unless otherwise noted:	
761	Assess for AEs	
762	 Assess COVID signs and symptoms 	
763 764	 Document all current medications, including medications over the counter and herbal medications 	
765	 Document patient's status as an outpatient, subsequently hospitalized, or died 	
766	 Perform clinical assessment by patient report and vital signs (temperature and oxygen 	
767	saturation)	
768	Evaluate for increased severity of COVID-19-related disease	
769	• Collect temperature and oximetry data daily, with the caveat that if O2 goes below 92%, an	
770	addition oximeter reading should be taken 2 hours later. If the follow-up O2 saturation remains	
771	below 92%, the participant will be referred to their Primary Care Physician (PCP) or to the local	
772	Emergency Department.	
773	• Collect oropharyngeal swab samples for viral shedding on days 1, (baseline), 3, 7, 10, 14 (courier	
774	transport of specimen)	
775	• Collect fecal samples for viral shedding as measured by fecal PCR on days 1, (baseline), 3, 7, 10,	
776	14 and 21 (courier transport of specimen)	
777		
778	Final Study Visit (Non-hospitalized Participants)	
779	The following procedures will be performed at the final post treatment visit:	
780	Assess for AEs Assess for complications following treatments	
781	Assess for complications following treatments	
782 783	 Document all current medications, including medications over the counter and herbal medications 	
784	 Perform clinical assessment to evaluate for increased severity of COVID-19-related diseases 	
785	• Perform clinical assessment to evaluate for increased sevency of covid-13-related diseases	
786	Early Termination/Hospitalization	
787	All participants have the right to withdraw from study participation at any time during the study. If, for	
788	whatever reason, a participant withdraws from the study or is hospitalized, an Early Termination Visit	
789	will be performed.	
790 701	The following procedures will be performed at the Early Termination Visit	
791 792	 The following procedures will be performed at the <i>Early Termination Visit</i>: Assess for adverse events 	
793	 Assess for complications following treatments 	
794	 Document all current medications, including medications over the counter and herbal 	
795	medications	
796	 Perform clinical assessment (as deemed feasible if hospitalized) 	

Evaluate for increased severity of COVID-19-related disease •

799 If clinical evaluation is deemed not feasible due to patient condition, the Study Team will collect *Early* 800 Termination Visit data via the Electronic Medical Record.

- A 30-day follow-up call and AE assessment for those patients who are hospitalized will be performed. 801
- 802 8.2

SAFETY AND OTHER ASSESSMENTS

803

804 For Study procedures and evaluations to be done as part of the study to monitor safety and support the understanding of the study intervention's safety refer to Section 1.2, Schedule of Activities and Section 805 8.1 Study Assessments. 806

807

808 809

8.3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS

Adverse event data will be summarized for all participants in the safety population. Site-reported serious 810

adverse events and unexpected adverse drug reactions will be summarized as participant-based counts 811

and percentages by AE category. MedDRA system organ class and preferred term In addition, participant 812

- 813 listings will be provided for serious, unexpected, and unanticipated adverse reactions. Any adverse
- events leading to discontinuation of study drug or death will also be listed for all participants. 814
- 815

Definition of Adverse Event (AE) 816

- 817 An AE is defined as any unanticipated medical occurrence regardless to relationship of the investigative
- 818 arm of the trial. An AE can be any unintended sign, lab abnormality, symptom, or disease associated
- with the trial. Any abnormality that presents during a medical test are to be defined as an AE if it 819
- produces clinical signs and/or symptoms, requires intervention, or deemed clinically significant by the 820
- 821 Investigator.
- 822

823 The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for AE reporting the following study-specific AEs: 824

- 825 Cough •
- 826 • Dyspnea
- Hypoxia 827 •
- Nausea 828 •
- Vomiting 829 •
- 830 Abdominal pain •
- Pruritus 831 •
- Loss of appetite 832 •
- Dizziness 833 •
- 834 Skin rash •
- 835
- 836 Definition of Serious Adverse Event (SAE)

837		
838	An AE is considered se	rious if it results in any of the following:
839	 results in deat 	h;
840	 is life-threater 	ing (places the subject at immediate risk of death from the event as it occurred);
841	 requires inpat 	ent hospitalization or prolongation of existing hospitalization;
842	results in a per	sistent or significant disability/incapacity;
843	 results in a cor 	ngenital anomaly/birth defect; or
844	 any other adve 	erse event that, based upon appropriate medical judgment, may jeopardize the
845	subject's healt	h and may require medical or surgical intervention to prevent one of the other
846	outcomes liste	d in this definition
847		
848	Definition of Unexpec	ted Adverse Reaction (UAE)
849	An adverse reaction, the	ne nature or severity of which is not consistent with the applicable product
850	information (e.g. Prod	uct Information/Summary of Product Characteristics). This would include any SAE
851	on health or safety, an	y life-threatening problem or death caused by, or associated with a drug; or any
852	other unanticipated se	rious problem associated with a drug that relates to the rights, safety, or welfare
853	of subjects.	
854		
855	8.3.1 CLASSIFICAT	ON OF AN ADVERSE EVENT.
856	8.3.1.1 SEVERITY O	FEVENT
857	:	
857 858	All AEs will be assessed	by the study clinician using the CTCAE V. 5.0
857 858 859	All AEs will be assessed Grade 1: Mild; asy	by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only;
857 858 859 860	 All AEs will be assessed Grade 1: Mild; asy intervention not ir 	l by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated.
857 858 859	 All AEs will be assessed Grade 1: Mild; asy intervention not ir Grade 2: Moderat 	l by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated. e; minimal, local or noninvasive intervention indicated
857 858 859 860 861	 All AEs will be assessed Grade 1: Mild; asy intervention not ir Grade 2: Moderat Grade 3: Severe o 	l by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated.
857 858 859 860 861 862	 All AEs will be assessed Grade 1: Mild; asy intervention not ir Grade 2: Moderat Grade 3: Severe o 	l by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated. e; minimal, local or noninvasive intervention indicated r medically significant but not immediately life-threatening; hospitalization or
857 858 859 860 861 862 863	 All AEs will be assessed Grade 1: Mild; asy intervention not in Grade 2: Moderat Grade 3: Severe o prolongation of home 	l by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated. e; minimal, local or noninvasive intervention indicated r medically significant but not immediately life-threatening; hospitalization or
857 858 859 860 861 862 863 864	 All AEs will be assessed Grade 1: Mild; asy intervention not in Grade 2: Moderat Grade 3: Severe o prolongation of ho 8.3.1.2 RELATIONSI 	d by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated. e; minimal, local or noninvasive intervention indicated r medically significant but not immediately life-threatening; hospitalization or spitalization indicated
857 858 859 860 861 862 863 864 865 866	 All AEs will be assessed Grade 1: Mild; asy intervention not in Grade 2: Moderat Grade 3: Severe o prolongation of ho 8.3.1.2 RELATIONSI A Study Team physicia 	by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated. e; minimal, local or noninvasive intervention indicated r medically significant but not immediately life-threatening; hospitalization or spitalization indicated
857 858 859 860 861 862 863 864 865	 All AEs will be assessed Grade 1: Mild; asy intervention not ir Grade 2: Moderat Grade 3: Severe o prolongation of ho 8.3.1.2 RELATIONSI A Study Team physicia following categories: 	d by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated. e; minimal, local or noninvasive intervention indicated r medically significant but not immediately life-threatening; hospitalization or spitalization indicated HIP TO STUDY INTERVENTION n will oversee the evaluation of patient reported severity of AEs using the
857 858 859 860 861 862 863 864 865 866 866 867	 All AEs will be assessed Grade 1: Mild; asy intervention not in Grade 2: Moderat Grade 3: Severe or prolongation of how 8.3.1.2 RELATIONSI A Study Team physicial following categories: Relationship to Study 	d by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated. e; minimal, local or noninvasive intervention indicated r medically significant but not immediately life-threatening; hospitalization or spitalization indicated HIP TO STUDY INTERVENTION n will oversee the evaluation of patient reported severity of AEs using the Products
857 858 859 860 861 862 863 864 865 866 866 867 868 869	 All AEs will be assessed Grade 1: Mild; asy intervention not ir Grade 2: Moderat Grade 3: Severe o prolongation of ho 8.3.1.2 RELATIONSI A Study Team physicia following categories: Relationship to Study All AEs must have thei 	d by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated. e; minimal, local or noninvasive intervention indicated r medically significant but not immediately life-threatening; hospitalization or spitalization indicated HIP TO STUDY INTERVENTION n will oversee the evaluation of patient reported severity of AEs using the Products
857 858 859 860 861 862 863 864 865 866 867 868 869 870	 All AEs will be assessed Grade 1: Mild; asy intervention not in Grade 2: Moderat Grade 3: Severe or prolongation of how 8.3.1.2 RELATIONSI A Study Team physicial following categories: Relationship to Study All AEs must have their evaluates the participation 	 d by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated. e; minimal, local or noninvasive intervention indicated r medically significant but not immediately life-threatening; hospitalization or spitalization indicated HIP TO STUDY INTERVENTION n will oversee the evaluation of patient reported severity of AEs using the Products r relationship to study intervention assessed by the clinician who examines and int based on temporal relationship and his/her clinical judgment. The degree of
857 858 859 860 861 862 863 864 865 866 867 868 869 870 871	 All AEs will be assessed Grade 1: Mild; asy intervention not in Grade 2: Moderat Grade 3: Severe or prolongation of how 8.3.1.2 RELATIONSI A Study Team physicial following categories: Relationship to Study All AEs must have their evaluates the participation 	d by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated. e; minimal, local or noninvasive intervention indicated r medically significant but not immediately life-threatening; hospitalization or spitalization indicated HIP TO STUDY INTERVENTION n will oversee the evaluation of patient reported severity of AEs using the Products
857 858 859 860 861 862 863 864 865 866 867 868 869 870	 All AEs will be assessed Grade 1: Mild; asy intervention not ir Grade 2: Moderat Grade 3: Severe o prolongation of ho 8.3.1.2 RELATIONSI A Study Team physicia following categories: Relationship to Study All AEs must have thei evaluates the participation categories 	 I by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated. e; minimal, local or noninvasive intervention indicated r medically significant but not immediately life-threatening; hospitalization or spitalization indicated HIP TO STUDY INTERVENTION n will oversee the evaluation of patient reported severity of AEs using the Products r relationship to study intervention assessed by the clinician who examines and int based on temporal relationship and his/her clinical judgment. The degree of ty will be graded using the categories below.
857 858 859 860 861 862 863 864 865 866 867 868 869 870 871	 All AEs will be assessed Grade 1: Mild; asy intervention not in Grade 2: Moderat Grade 3: Severe or prolongation of how 8.3.1.2 RELATIONSI A Study Team physicial following categories: Relationship to Study All AEs must have their evaluates the participation 	 d by the study clinician using the CTCAE V. 5.0 mptomatic or mild symptoms; clinical or diagnostic observations only; dicated. e; minimal, local or noninvasive intervention indicated r medically significant but not immediately life-threatening; hospitalization or spitalization indicated HIP TO STUDY INTERVENTION n will oversee the evaluation of patient reported severity of AEs using the Products r relationship to study intervention assessed by the clinician who examines and int based on temporal relationship and his/her clinical judgment. The degree of

	medical condition or intervention, which could explain the occurrence of such an event.
Possibly:	There is no clear relationship between the AE and the drug or study procedure; however, one cannot conclude that there is no relationship.
Unrelated:	There is no relationship between the AE and the drug or study procedure. This may include but is not limited to the incident being an expected outcome of a previously existing or concurrent disease, concomitant medication or procedure the participant experienced.

874 8.3.1.3 EXPECTEDNESS

875 Study Team members who are clinically qualified (e.g., a physician co- Investigator) will be responsible 876 for determining whether an AE is expected or unexpected. An AE will be considered unexpected if the

877 nature, severity, or frequency of the event is not consistent with the risk information previously

878 described for the study products. This information will be provided to the IRB, to the Study Sponsor, and

879 to any relevant governmental agency with regulatory or public health authority.

880

8.3.2 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW-UP

881 The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 882 interviews of a study participant presenting for medical care. 883

884

885 All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the appropriate CRF. Information to be collected includes event description, time of onset, clinician's 886 assessment of severity, relationship to study product (assessed only by those with the training and 887 authority to make a diagnosis), and time of resolution/stabilization of the event. All AEs occurring while 888 on study must be documented appropriately regardless of relationship. All AEs will be followed to 889 890 adequate resolution.

891

892 8.3.3 ADVERSE EVENT REPORTING

893 Adverse event data will be summarized for all participants in the safety population. Serious adverse 894 events and unexpected adverse drug reactions will be summarized as participant-based counts and percentages by AE category. In addition, participant listings will be provided for serious, unexpected, 895 and unanticipated adverse reactions. Any adverse events leading to discontinuation of study drug or 896 death will also be listed for all participants. 897

898

900

899

8.3.4 SERIOUS ADVERSE EVENT REPORTING

901 Study team members who are qualified will immediately report any serious adverse event, whether or not considered study intervention related, including those listed in the protocol and must include an 902

01022021

903	assessment of whether there is a reasonable possibility that the study intervention caused the event.
904	Study endpoints that are SAEs must be reported in accordance with the protocol.

905		
906	8.3.5 REPORTING EVENTS TO PARTICIPANTS	
907		
908 909	AEs, SAEs and UPs will be reported to IRB as outlined in Sections 8.3.5, 8.3.6 and 8.4.2	
910	8.3.6 EVENTS OF SPECIAL INTEREST	
911		
912 913	N/A	
914	8.3.7 REPORTING OF PREGNANCY	
914 915	8.5.7 REPORTING OF PREGNANCE	
916	During the Informed Consent discussion, the MD study Investigator will ask women of childbearing	
917	potential if they are pregnant. That yes/ no response will be recorded. We will not exclude women who	
918	are of childbearing years or pregnant. We will collect pregnancy status information at the time of	
919	enrollment. Niclosamide is a Category B (animal studies show no risks, but there are no controlled	
920	studies in pregnant women). Category B drugs include prenatal vitamins, acetaminophen and several	
921	other medications used routinely and safely during pregnancy.	
922		
923	In addition to recording whether women of childbearing age are pregnant at the time of study	
924	enrollment, we will also record their breastfeeding status. For enrolled subjects who are pregnant or	
925	breastfeeding, we will include follow up a specific query for any adverse effects on pregnancy and/or	
926 927	breastfeeding infant during the course of the study.	
928	8.4 UNANTICIPATED PROBLEMS	
929	8.4.1 DEFINITION OF UNANTICIPATED PROBLEMS (UP):	

PATED PROBLEMS (UP): 930 The Office for Human Research Protections (OHRP) considers unanticipated problems involving risks to 931 participants or others to include, in general, any incident, experience, or outcome that meets all the 932

- following criteria: 933 934 Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 935 described in the protocol-related documents, such as the Institutional Review Board (IRB)-936 approved research protocol and informed consent document; and (b) the characteristics of the 937 938 participant population being studied; 939 Related or possibly related to participation in the research ("possibly related" means there is a 940 reasonable possibility that the incident, experience, or outcome may have been caused by the procedures involved in the research); and 941 Suggests that the research places participants or others at a greater risk of harm (including 942
- 943 physical, psychological, economic, or social harm) than was previously known or recognized.
- 944

89.445.2 UNANTICIPATED PROBLEM REPORTING

	Selker Pl	01022021
947	The investigator will report unanticipated problems (UPs) to the reviewing Institutional Review B	oard
948	(IRB). The UP report will include the following information:	

545	
950• 951 952 953 954 955	 Protocol identifying information: protocol title and number, Pl's name, and the IRB project number; A detailed description of the event, incident, experience, or outcome; An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP; A description of any changes to the protocol or other corrective actions that have been taken or are proposed in response to the UP.
956 957 958 959 960 961 962 963	 To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline: UPs that are SAEs will be reported to the IRB within 5 working days of the investigator becoming aware of the event. A Study Team evaluation of an UP will be performed with a report of results of such evaluation will be provided to the reviewing IRB by the PI within 5 working days. All other Reportable New Information will be reported to the IRB as per the policy.
964 965 966 967	8.4.3 REPORTING UNANTICIPATED PROBLEMS TO PARTICIPANTS AEs, SAEs and UPs will be reported to IRB as outlined in Sections 8.3.5, 8.3.6 and 8.4.2
968	9 STATISTICAL CONSIDERATIONS
969	9.1 STATISTICAL HYPOTHESES
970 971 972 973 974	The null hypothesis is that the proportion of participants with respiratory viral clearance at Day 3 is the same in both treatment groups. The alternative hypothesis is that they are different.
975	9.2 SAMPLE SIZE DETERMINATION
976 977 978 979 980 981 982 982 983 984	For the primary efficacy endpoint of respiratory virologic clearance at Day 3 measured by oropharyngeal viral shedding we assume that on Day 3, 50% of participants in the niclosamide group who have a positive result on Day 1 (prior to dosing) will have a negative test results and 15% in the placebo group. With 40 participants per group we have 89% power to show a statistically significant difference between groups at Day 3 using Fisher's Exact test at the two-sided 0.05 significance level. Assuming that 40% of randomized participants have a positive respiratory test result, 200 participants will be required to be randomized into the study.
985	9.3 POPULATIONS FOR ANALYSES
986 987	Intention-to-Treat (ITT) Analysis Dataset (all randomized participants)

- Modified Intention-to-Treat Analysis Dataset (participants who took at least one dose of study
 intervention, have a positive test result on Day 1 and have Day 3 oropharyngeal sample results
 available for analysis.
- 991 Safety Analysis Dataset: participants who took at least one dose of study intervention
- Per-Protocol Analysis Dataset: subset of the participants in the full analysis (ITT) set who took at
 least 80% of study intervention and had no protocol violations that would affect the primary
 efficacy endpoint.
 - Other Datasets that may be used for sensitivity analyses
- 995 996 997

9.4 STATISTICAL ANALYSES

998 9.4.1 GENERAL APPROACH

1000 Baseline demographic and clinical characteristics and other results will be summarized using descriptive 1001 summary statistics. Data collected in the trial will be summarized overall and by treatment arm. For 1002 continuous variables, results within each treatment arm will be summarized with the numbers of observations, mean, standard deviation, minimum, and maximum, as well as the 95% confidence 1003 1004 interval for the mean. For treatment comparisons, the difference between the two treatment arms will 1005 be summarized with the difference of the two means and 95% confidence interval for the difference of 1006 the means. These calculations will be done under the assumption that the data for the two arms are independent and approximately normal in distribution. If not otherwise specified, the confidence 1007 1008 interval for the difference of two means is calculated assuming unequal variance between the two 1009 groups. If asymptotic assumptions fail, nonparametric summary statistics (medians, 25th and 75th 1010 percentiles) may be displayed as an alternative. In addition, more appropriate non-parametric tests will 1011 be considered if the assumptions for the parametric tests are violated. For the comparison of two 1012 independent samples, if the data are not normally distributed, Wilcoxon rank-sum test will be 1013 performed instead of the parametric t-test.

1014

For categorical variables, results within each arm will be summarized with participant counts, percentages, and 95% confidence intervals. The differences between the two treatment arms will be summarized with the difference in percentages and the asymptotic 95% confidence interval for the difference of two percentages.

1019

Survival analysis techniques will be used to analyze the time-to-event variables. Survival curves will be
 constructed using Kaplan-Meier estimates. Log-rank test results will be computed for comparison of
 survival distributions. Summary tables for safety and efficacy endpoints will include event rates (Kaplan Meier estimates of event rates), relative risk, confidence interval for the relative risk, the difference in
 means/rates, the confidence interval for difference in means/rates, and the p-value.

- 1025
- 1026

For the primary efficacy endpoint, respiratory Clearance at Day 3 will be summarized by treatment group and the difference will be tested using a two-sided Fisher's Exact Test at the 0.05 significance level. The corresponding confidence interval for the difference in proportions will be calculated.

01022021

1031	Every effort will be made to ensure the oropharyngeal samples are collected at all time points specified
1032	by the protocol even if the subject discontinues the study drug. The primary analytic sample will be the

- 1033 mITT cohort
- 1034

1036

- 1035 All analyses will be repeated using the per-protocol population.
- 1037 9.4.2 ANALYSIS OF THE SECONDARY ENDPOINT(S) 1038 1039 Secondary Efficacy Analysis Fecal viral clearing at day 14 will be summarized by treatment group and the difference will 1040 • 1041 be tested separately for each day using a two-sided Fisher's Exact Test. 1042 Respiratory viral shedding as measured on days 1, 3, 7, 10, 14 will be compared between 1043 ٠ treatment groups using repeated measures analysis. 1044 1045 1046 Fecal viral shedding as measured on days 1, 3, 7, 10, 14 and 21 will be compared between ٠ treatment groups using repeated measures analysis. 1047 1048 1049 We plan to consider additional analysis approaches including but not limited to: time to negative COVID-1050 19 test as determined by PCR using oropharyngeal and/or fecal samples; longitudinal analysis of 1051 continuous measures such as body temperature and O2 saturation; The proportion of participants in 1052 each treatment group who progress to severe COVID disease will be compared using a two-sided z test 1053 with continuity correction. The corresponding confidence interval for the difference in proportions will 1054 be calculated. 1055 All secondary endpoint analyses will be performed for the mITT and PP populations at the 0.05 1056 1057 significance level. No adjustment for multiple testing will be performed. 1058 1059 9.4.3 SAFETY ANALYSES 1060 Adverse event data will be summarized for all participants in the safety population. Site-reported serious 1061 1062 adverse events and unexpected adverse drug reactions will be summarized as participant-based counts 1063 and percentages by AE category. 1064 In addition, participant listings will be provided for serious, unexpected, and unanticipated adverse 1065 1066 reactions. Any adverse events leading to discontinuation of study drug or death will also be listed for all 1067 participants. 1068 1069 9.4.4 BASELINE DESCRIPTIVE STATISTICS 1070 Demographic characteristics and medical history, adverse events, COVID disease signs and symptoms 1071 1072 and treatment compliance will be summarized and compared between treatment groups. The details of 1073 the statistical analyses will be included in the *Statistical Analysis Plan*.

9.4.5 PLANNED INTERIM ANALYSES
N/A
9.4.6 SUB-GROUP ANALYSES
N/A
9.4.7 TABULATION OF INDIVIDUAL PARTICIPANT DATA
N/A
9.4.8 EXPLORATORY ANALYSES
A detailed description of all statistical analyses will be presented in the <i>Statistical Analysis Plan.</i>
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1 REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS.
10.1.1 INFORMED CONSENT PROCESS
10.1.1.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO PARTICIPANTS
Consent describing in detail the study intervention, study procedures, and risks will be provided to the participant and documentation of informed consent will be required prior to administering study interventions. Non-English speakers will be enrolled using interpreters and IRB approved Short Forms per the IRB's Short Form policy.
10.1.1.2 CONSENT PROCEDURES AND DOCUMENTATION
Informed consent (IC) is a process that is initiated prior to the individual's agreeing to participate in the study and continues throughout the individual's study participation. The PI or physician co-Investigator will explain the research study to the participant and answer any questions that may arise. Utilizing the telehealth platform, an explanation will be provided in terms suited to the participant's comprehension of the purposes, procedures, and potential risks of the study and of their rights as research participants. Potential participants will have the opportunity to ask questions. The participants will have the opportunity to discuss the study with their family or surrogates or think about it prior to agreeing to participate. They will be informed that participation is voluntary and that they may withdraw from the study at any time, without prejudice. The rights and welfare of the participants will be protected by emphasizing to them that the quality of their medical care will not be adversely affected if they decline to participate in this study.

Version 8.0

NIC for COVID Protocol 00000605

	Selker Pl 01022021
1115	FDA regulations generally require that the informed consent of a trial participant be documented by the
1116	use of a written consent form that has been approved by the IRB and signed and dated by the subject at
1117	the time of consent (21 CFR 50.27(a)). Considering COVID-19 infection control measures, if the
1118	technology is available, current FDA guidance suggests that electronic methods of obtaining informed
1119	consent should be considered as follows:
1120	
1121 1122	• To ensure that patients are approached in a consistent fashion, a standard process should be used that will accomplish the following:
1123	 Identification of who is on the call or telemedicine visit
1124	 Review of the IC with the patient by the investigator (or their designee) and response to
1124	any questions the patient may have
1126	 Confirmation by the witness that the patient's questions have been answered
1127	 Confirmation by the investigator that the patient is willing to participate in the trial and
1128	sign the informed consent document while the witness is listening on the phone
1129	 Verbal confirmation by the patient that they would like to participate in the trial and
1130	that they have signed and dated the informed consent document that is in their
1131	possession.
1132	
1133	• If the signed informed consent document cannot be collected from the patient's location and
1134	included in the study records, FDA considers the following option acceptable to provide
1135	documentation that the patient signed the informed consent document:
1136	 A dated attestation by the witness who participated in the call and by the investigator
1137	that the patient confirmed that they agreed to participate in the study and signed the
1138	informed consent.
1139	
1140	For this study involving participants with COVID-19 positivity, in accordance with FDA guidance, the
1141	following steps will be performed while obtaining the IC by phone or telehealth video chat from the
1142	Subject.
1143	
1144	1) Purpose of the study and the potential risks/benefits of the use of the Investigational Agent
1145	Niclosamide in the treatment of confirmed COVID-19 infection will discussed in detail by the
1146	principal investigator or sub-investigator (PI/Sub-I) with the subject prior to obtaining the IC.
1147	Opportunity to review the ICF (informed consent form) prior to or during the discussion will be
1148	provided. Adequate time for discussion between the PI/Sub-I will be given to the potential
1149	participant. After review of the IC, any questions that the potential participant has will be
1150	addressed during or after review of the IC.
1151	
1152	2) Availability and/or possibility of other potential treatment options will be discussed with the
1153	participant.
1154	

01022021	
----------	--

- 3) A second member of the study team will be present on the phone or video chat during the entire discussion. The witness will ask the potential participant if they understand the contents of the discussion and if they have any questions to address. The participant will be informed that they can ask questions at any time during the trial.
 1159
 4) The PI/Sub-I will sign the ICF along with the witness. Copies of the signed form will be placed in the patient's medical record and provided to the participant.
- 5) This document will be placed into the electronic medical record and electronically signed, and time
 stamped by the investigator. In **de-identified form,** it will be the study source document for
 documenting the process of obtaining ICF. A copy of the electronically signed consent (signed by
 the witness and investigator) is either emailed, sent by US Mail to subject.
- 1167

10.1.2 STUDY DISCONTINUATION AND CLOSURE

1168

1169 This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 1170 cause. Written notification, documenting the reason for study suspension or termination, will be 1171 provided by the suspending or terminating party to study participants, investigator, funding agency, and 1172 regulatory authorities. If the study is prematurely terminated or suspended, the Principal Investigator 1173 (PI) will promptly inform study participants and the Institutional Review Board (IRB) for the termination 1174 or suspension. Study participants will be contacted, as applicable, and be informed of changes to study 1175 visit schedule.

1176

1178

1179

1180

1181

1182

1177 Circumstances that may warrant termination or suspension include, but are not limited to:

- Determination of unexpected, significant, or unacceptable risk to participants
- Insufficient compliance to protocol requirements
 - Data that are not sufficiently complete and/or evaluable
 - Determination that the primary endpoint has been met

1183 The study may resume once concerns about safety, protocol compliance, and data quality are addressed 1184 and the IRB.

1185

1186 10.1.3 CONFIDENTIALITY AND PRIVACY

1187

Participant confidentiality and privacy is strictly held in trust by the participating investigators, their staff, and the sponsor(s) and their interventions. This confidentiality is extended to cover testing of biological samples in addition to the clinical information relating to participants. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. No information concerning the study, or the data will be released to any unauthorized third party without

1193 prior written approval of the sponsor.

NIC for COVID Protocol 00000605 Selker Pl

01022021

- All research activities will be conducted in as private a setting as possible. The use of the telehealth
- video platform will include participant instruction on using the platform in a private setting or with a
- 1197 family member/ significant other via Facetime as described in the Study Intervention.
- 1198
- 1199 Representatives of the Institutional Review Board (IRB), regulatory agencies or pharmaceutical company 1200 supplying study product may inspect all documents and records required to be maintained by the
- 1201 investigator, including but not limited to, medical and pharmacy records for the participants in this
- 1202 study. The clinical study site will permit access to such records.
- 1203

1204 The study participant's contact information will be securely stored at each clinical site for internal use 1205 during the study. At the end of the study, all records will continue to be kept in a secure location for as 1206 long a period as dictated by the reviewing IRB, Institutional policies, or sponsor requirements.

- 1207 The Principal Investigator will be responsible to ensure the study is conducted in accordance with the
- 1208 protocol, Good Clinical Practice (GCP), applicable regulatory requirements, and that the data recorded is

valid. To achieve this objective, the study will be continuously monitored, and the study conduct

- 1210 reviewed on a weekly basis by the Study Team.
- 1211 Monitoring will be conducted to ensure that the rights and well-being of human participants are
- 1212 protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of
- 1213 the trial follows the currently approved protocol/amendment(s), with GCP, and with applicable
- 1214 regulatory requirement(s).
- A Clinical Monitoring Plan will be created by the Study Team and will describe in detail the personnel who will conduct the monitoring, at what frequency monitoring will be done, at what level of detail monitoring will be performed, and the distribution of monitoring reports.
- 1218
- 1219 10.1.4 FUTURE USE OF DATA
- 1220 The collection of personal patient information will be limited to the amount necessary to achieve the 1221 aims of the research, so that no unneeded sensitive information is being collected.
- Data from the EDC will be exported into Excel or SAS file format (password protected), which will then be used for data analysis. Only de-identified, not including the participant's contact or identifying information data will be used for data analysis.
- 1225

1226 10.1.5 KEY ROLES AND STUDY GOVERNANCE

1227 Provide the name and contact information of the Principal Investigator.

Principal Investigator	
Harry Selker, MD	

		01022021	
	Institute for Clinical Research and Health Policy Studies		
	Tufts Clinical and Translational Science Institute (CTSI)		
	Tufts University		
	Tufts Medical Center		
	800 Washington Street, # 63, Boston, MA 02111		
	Phone: (617) 636-5009		
	Fax: (617) 636-8023		
	Email		
1228			
1229			
1230	10.1.6 SAFETY OVERSIGHT		
1231	An appropriately credentialled Independent Safety Monitor (ISM) without association to		
1232	conflicts of related to the study will monitor the data on a weekly basis and make recon	nmendations to	
1233	the PI with respect to the:		
1234	Safety of the trial participants including adverse events (AEs), serious adverse events	vents (SAE's),	
1235	and unexpected problems		
1236	The Independent Safety Monitor will review and evaluate all AEs and SAEs in a l	olinded fashion,	
1237	however, can be unblinded as needed.		
1238	 The ISM will have access to unblinded SAE rates for participants randomized to please a frage serieur AE awill also be server and between the two study 		
1239	placebo. Rates of non-serious AEs will also be compared between the two study		
1240	Subjects will be monitored for adverse events (AEs) and serious adverse events (SAEs).	÷	
1241	incidence of treatment related SAEs in the niclosamide treatment group vs placebo will	be added to the	
1242	protocol as the stopping threshold		
1243			
1244	The PI is personally responsible for conducting and supervising the conduct of human su	-	
1245	by protecting the rights, safety, and welfare of subjects under the investigator's care. T		
1246	ensure that all the research conducted is done so in an ethical manner and in accordance		
1247	federal, state, and local laws and regulations, institutional policies/procedures, the stud		
1248	and the requirements of the IRB. Oversight is defined as management by overseeing the		
1249	operation of a person or group, watchful care, superintendence, general supervision. Ar		
1250	as a PI has voluntarily accepted these responsibilities and is expected to fully comply wi	th these	
1251	requirements. To provide PI oversight and to ensure that the rights, safety, and welfare of research		
1252	subjects is protected the PI will, at a minimum, confirm:		
1253	 Any individual to whom a task is delegated is qualified by education, training, and 	nd experience to	
1254	perform the task.		
1255	• There is adequate training for all staff participating in the conduct of the study		
1256	• The PI or another qualified individual associated with the study is available to s	tudy subjects to	
1257	answer questions or provide care during the conduct of the research		
1258	• All research staff adhere to the research plan (i.e., inclusion/exclusion criteria, s	afety	
1259	assessments, safety monitoring and reporting of unanticipated problems).		
1260			
1261	Expected Oversight Practices		

	Selker Pl	01022021
52	•	The PI will work closely with the study team to ensure oversight of the research study and the
3		necessary documentation of such activities. A sub- Investigator can cover for the PI when he is
4		unavailable or is on vacation.
5	•	A Delegation of Authority Log will be completed prior to opening to accrual. This log will be
5		maintained accurately during the life of the study.
,	•	A Training Log will be completed prior to opening to accrual. This log will be maintained
3		accurately during the life of the study.
	•	The PI or delegated physician Investigator will sign-off on all study-related documents (i.e.,
		eligibility verification) prior to subjects beginning study treatment per protocol to ensure the
		safety of the study participants
	•	The PI or delegated physician Investigator will evaluate and ascribe attribution, sign-off on all
		AEs and SAEs.
	•	The PI and Study Team will establish the method in which they will consistently communicate.
		At a minimum, this is intended to be through a combination of electronic, audio, and face to
		face interactions. Details and specifics of these interactions will be established by the PI and
		Study Team prior to activation of each study.
	•	Communication regarding SAEs will be documented in real-time. If the PI is not available, the
		delegated physician Investigator should be notified.
	•	Regular meetings with the PI to discuss subject participation, including AEs and treatment, will
		be established to ensure adequate oversight. This is in addition to the immediate availability of
		the PI, or delegated physician Investigator, to address SAE, protocol interpretation, safety
		monitoring or other urgent clinical needs. Involvement of the treating sub-investigator is
		recommended but not required.
	•	Timely and accurate documentation of oversight is required and will be provided by the PI
		consistent with FDA1572. The nature of oversight documentation is through written and
		electronic means.
	٠	The PI or physician Investigator will complete urgent documents including initial SAE review and
		sign-off within 24 hours of notification of the event.
	•	All non-urgent regulatory documents including IRB submission/revisions, AE attribution
		assignments, AE grading will be completed by the PI or physician Investigator within 48 hours.
	•	Additional study documents including but not limited to research notes, email correspondences,
		and study logs are to be reviewed at least on a weekly basis by the PI and included with research
		documentation.
	10.1.7	CLINICAL MONITORING
	Clinical	monitoring will be conducted to ensure that the rights and well-being of trial participants are
)	Chinean	membering min be conducted to ensure that the rights and wen being of that participants are

1299 Clinical monitoring will be conducted to ensure that the rights and well-being of that participants are
 1300 protected, that the reported trial data are accurate, complete, and verifiable, and that the conduct of
 1301 the trial is in compliance with the currently approved protocol/amendment(s), with International

	NIC for COVID Version 8.0 Protocol 00000605 Selker PI 01022021
1302 1303	Conference on Harmonisation Good Clinical Practice (ICH GCP), and with applicable regulatory requirement(s).
1304 1305 1306	Refer to Section 10.1.6 Safety Oversite for details.
1307 1308	10.1.8 QUALITY ASSURANCE AND QUALITY CONTROL
1309 1310 1311 1312	Quality control (QC) procedures will be implemented beginning with the data entry system and data QC checks that will be run on the database will be generated. Any missing data or data anomalies will be communicated to study PI or designee for resolution.
1313 1314 1315 1316 1317 1318	Following written Standard Operating Procedures (SOPs), the PI and co- Investigators will verify that the clinical trial is conducted, and data are generated, and biological specimens are collected, documented (recorded), and reported in compliance with the protocol, International Conference on Harmonisation Good Clinical Practice (ICH GCP), and applicable regulatory requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).
1319 1320 1321	The investigational site will provide direct access to all source data/documents, and reports for the purpose of monitoring, auditing and inspection by local and regulatory authorities.
1321 1322 1323	10.1.9 DATA HANDLING AND RECORD KEEPING.
1324	10.1.9.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES
1325 1326 1327 1328 1329	Data collection is the responsibility of the Study Staff under the supervision of the Investigator. The Investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.
1330 1331 1332	All source documents will be completed in a neat, legible manner to ensure accurate interpretation of data.
1332 1333 1334 1335 1336 1337	Any hardcopies of study visit worksheets will be provided for use as source document worksheets for recording data for each participant enrolled in the study. Data recorded in the electronic case report form (eCRF) derived from study source documents will be consistent with the data recorded on the source documents.
1338 1339 1340 1341 1342	Clinical data, AEs, concomitant medications, and any other data collected from participants will be entered into a REDCap database. The data system includes password protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the source documents.
1342	10.1.9.2 STUDY RECORDS RETENTION

W	We will follow the IRB's HRP-073 - SOP - Records Retention Timeframe – Investigators (0.03)			
1	0.1.10 PROTOCOL DEVIATIONS			
H n	protocol deviation is any noncompliance with the cl armonisation Good Clinical Practice (ICH GCP), or Ma oncompliance may be either on the part of the parti- esult of deviations, corrective actions are to be devel	anual of Procedures (MOP) requirements. The cipant, the Investigator, or the Study Team. As a		
Ρ	 hese practices are consistent with ICH GCP: 4.5 Compliance with Protocol, sections 4.4 5.1 Quality Assurance and Quality Control 5.20 Noncompliance, sections 5.20.1, and rotocol deviations will be summarized by type of deviations will be participant-based. 	, section 5.1.1 5.20.2.		
1	0.1.11 PUBLICATION AND DATA SHARIN	G POLICY		
a p a	ne preparation and submittal for publication of man ccordance with a process determined by mutual writ articipating institutions. The publication or presenta oplicable privacy laws, including, but not limited to, t ct of 1996.	ten agreement among the study Sponsor and tion of any study results shall comply with all		
C รเ รเ	nis study will comply with the NIH Data Sharing Polic inical Trial Information and the Clinical Trials Registr uch, this trial will be registered at ClinicalTrials.gov, a ubmitted to ClinicalTrials.gov. In addition, every atter eviewed journals.	ation and Results Information Submission rule. As nd results information from this trial will be		
1	0.1.12 CONFLICT OF INTEREST POLICY			
ir co p w le	ne independence of this study from any actual or pe dustry, is critical. Therefore, any actual conflict of ir onduct, analysis, publication, or any aspect of this tri ersons who have a perceived conflict of interest will ay that is appropriate to their participation in the de adership in conjunction has established policies and sclose all conflicts of interest and will establish a me	terest of persons who have a role in the design, al will be disclosed and managed. Furthermore, be required to have such conflicts managed in a sign and conduct of this trial. The study procedures for all study group members to		

	NIC for COVID Protocol 00000605	Version 8.0
	Selker Pl	01022021
1384	10.2 ADDITIONAL CONSIDERATIONS	

10.3 ABBREVIATIONS

1388

AE	Adverse Event
ANCOVA	Analysis of Covariance
CFR	Code of Federal Regulations
CLIA	Clinical Laboratory Improvement Amendments
CMP	Clinical Monitoring Plan
COC	Certificate of Confidentiality
CONSORT	Consolidated Standards of Reporting Trials
CRF	Case Report Form
DCC	Data Coordinating Center
DHHS	Department of Health and Human Services
DSMB	Data Safety Monitoring Board
DRE	Disease-Related Event
EC	Ethics Committee
eCRF	Electronic Case Report Forms
FDA	Food and Drug Administration
FDAAA	Food and Drug Administration Amendments Act of 2007
FFR	Federal Financial Report
GCP	Good Clinical Practice
GLP	Good Laboratory Practices
GMP	Good Manufacturing Practices
GWAS	Genome-Wide Association Studies
HIPAA	Health Insurance Portability and Accountability Act
IB	Investigator's Brochure
ICH	International Conference on Harmonisation
ICMJE	International Committee of Medical Journal Editors
IDE	Investigational Device Exemption
IND	Investigational New Drug Application
IRB	Institutional Review Board
ISM	Independent Safety Monitor
ISO	International Organization for Standardization
ITT	Intention-To-Treat
LSMEANS	Least-squares Means
MedDRA	Medical Dictionary for Regulatory Activities
MOP	Manual of Procedures
MSDS	Material Safety Data Sheet
NCT	National Clinical Trial
NIH	National Institutes of Health
NIH IC	NIH Institute or Center
OHRP	Office for Human Research Protections
PI	Principal Investigator
QA	Quality Assurance
QC	Quality Control
SAE	Serious Adverse Event
SAP	Statistical Analysis Plan
L	

NIC for COVID Protocol 00000605 Selker Pl

SMC	Safety Monitoring Committee
SOA	Schedule of Activities
SOC	System Organ Class
SOP	Standard Operating Procedure
UP	Unanticipated Problem
US	United States

1389 1390

NIH-FDA Clinical Trial Protocol Template – v1.0 7 Apr 2017

1391 10.4 PROTOCOL AMENDMENT HISTORY

1392 The table below is intended to capture changes of IRB-approved versions of the protocol, including a

description of the change and rationale. A Summary of Changes table for the current amendment is
located in the Protocol Title Page.

1395

Version	Date	Description of Change	Brief Rationale

	NIC for COVID Protocol 00000605 Selker Pl	Version 8.0 01022021
1397	11 REFERENCES	01022021
1398 1399 1400	 Wu, Y., C. Guo, L. Tang, Z. Hong, J. Zhou, X. Dong, H. Yin, Q. Xiao, Y. Tang, X. Qu, L. Kuang Fang, N. Mishra, J. Lu, H. Shan, G. Jiang, and X. Huang, <i>Prolonged presence of SARS-CoV-</i> <i>RNA in faecal samples</i>. Lancet Gastroenterol Hepatol, 2020. 5(5): p. 434-435. 7158584 	-
1401 1402 1403	 Jeon, S., M. Ko, J. Lee, I. Choi, S.Y. Byun, S. Park, D. Shum, and S. Kim, Identification of an drug candidates against SARS-CoV-2 from FDA-approved drugs. bioRxiv, 2020: p. 2020.03.20.999730. 	ntiviral
1404 1405 1406	3. Jung, E., S. Nam, H. Oh, S. Jun, H.J. Ro, B. Kim, M. Kim, and Y.Y. Go, Neutralization of Aci Intracellular Vesicles by Niclosamide Inhibits Multiple Steps of the Dengue Virus Life Cyc. Vitro. Sci Rep, 2019. 9 (1): p. 8682. 6582152	
1407 1408 1409	 Cairns, D.M., D. Boorgu, M. Levin, and D.L. Kaplan, Niclosamide rescues microcephaly in humanized in vivo model of Zika infection using human induced neural stem cells. Biol O 2018. 7(1). 5829514 	
1410 1411	 Chen, W., R.A. Mook, Jr., R.T. Premont, and J. Wang, Niclosamide: Beyond an antihelmin drug. Cell Signal, 2018. 41: p. 89-96. 5628105 	ıthic
1412 1413 1414 1415	 Andersen, P.I., K. Krpina, A. Ianevski, N. Shtaida, E. Jo, J. Yang, S. Koit, T. Tenson, V. Hukk M.W. Anthonsen, M. Bjoras, M. Evander, M.P. Windisch, E. Zusinaite, and D.E. Kainov, <i>N</i> <i>Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharrington</i> Viruses, 2019. 11(10). 6832696 	lovel
1416 1417 1418	 Fan, X., J. Xu, M. Files, J.D. Cirillo, J.J. Endsley, J. Zhou, and M.A. Endsley, Dual activity of niclosamide to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis (Beijing). Tuberculosis (Edinb), 2019. 1165: p. S28-S33. 	
1419 1420 1421	 Jurgeit, A., R. McDowell, S. Moese, E. Meldrum, R. Schwendener, and U.F. Greber, Niclo a proton carrier and targets acidic endosomes with broad antiviral effects. PLoS Pathog, 8(10): p. e1002976. 3486884 	
1422 1423 1424	 Marrugal-Lorenzo, J.A., A. Serna-Gallego, J. Berastegui-Cabrera, J. Pachon, and J. Sanche Cespedes, <i>Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections</i>. 2019. 9(1): p. 17. 6327057 	
1425 1426 1427	 Wang, Y.M., J.W. Lu, C.C. Lin, Y.F. Chin, T.Y. Wu, L.I. Lin, Z.Z. Lai, S.C. Kuo, and Y.J. Ho, Ar activities of niclosamide and nitazoxanide against chikungunya virus entry and transmis Antiviral Res, 2016. 135: p. 81-90. 	
1428 1429	11. Xu, J., P.Y. Shi, H. Li, and J. Zhou, <i>Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.</i> ACS Infect Dis, 2020.	
1430 1431 1432 1433 1434	12. Xu, M., E.M. Lee, Z. Wen, Y. Cheng, W.K. Huang, X. Qian, J. Tcw, J. Kouznetsova, S.C. Oge Hammack, F. Jacob, H.N. Nguyen, M. Itkin, C. Hanna, P. Shinn, C. Allen, S.G. Michael, A. Simeonov, W. Huang, K.M. Christian, A. Goate, K.J. Brennand, R. Huang, M. Xia, G.L. Mir Zheng, H. Song, and H. Tang, <i>Identification of small-molecule inhibitors of Zika virus infe</i> <i>induced neural cell death via a drug repurposing screen.</i> Nat Med, 2016. 22 (10): p. 1101	ng, W. ction and

~ ~	~~	~ ~	~ -
01	.02	20	121

- 13. Wu, C.J., J.T. Jan, C.M. Chen, H.P. Hsieh, D.R. Hwang, H.W. Liu, C.Y. Liu, H.W. Huang, S.C. Chen, 1435 1436 C.F. Hong, R.K. Lin, Y.S. Chao, and J.T. Hsu, Inhibition of severe acute respiratory syndrome 1437 coronavirus replication by niclosamide. Antimicrob Agents Chemother, 2004. 48(7): p. 2693-6. 1438 434198 1439 14. Mazzon, M., A.M. Ortega-Prieto, D. Imrie, C. Luft, L. Hess, S. Czieso, J. Grove, J.K. Skelton, L. 1440 Farleigh, J.J. Bugert, E. Wright, N. Temperton, R. Angell, S. Oxenford, M. Jacobs, R. Ketteler, M. 1441 Dorner, and M. Marsh, Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry. Viruses, 2019. 11(2). 6410080 1442 15. Sekulovski, N., A.E. Whorton, T. Tanaka, Y. Hirota, M. Shi, J.A. MacLean, J.R.L. Mola, K. Groesch, 1443 P. Diaz-Sylvester, T. Wilson, and K. Hayashi, Niclosamide suppresses macrophage induced 1444 1445 inflammation in endometriosis. Biol Reprod, 2020. 16. Thatikonda, S., V. Pooladanda, and C.A.-O.h.o.o. Godugu, Repurposing an old drug for new use: 1446 1447 Niclosamide in psoriasis-like skin inflammation. (1097-4652 (Electronic)). 1448 17. Hochmair, M., B. Rath, L. Klameth, E. Ulsperger, C. Weinlinger, A. Fazekas, A. Plangger, R. 1449 Zeillinger, and G. Hamilton, Effects of salinomycin and niclosamide on small cell lung cancer and
- 1451
 18. Chai, W.H., Y.R. Li, S.H. Lin, Y.H. Chao, C.H. Chen, P.C. Chan, and C.H. Lin, Antihelminthic
 1452
 Niclosamide Induces Autophagy and Delayed Apoptosis in Human Non-small Lung Cancer Cells In 1453
 Vitro and In Vivo. Anticancer Res, 2020. 40(3): p. 1405-1417.

small cell lung cancer circulating tumor cell lines. Invest New Drugs, 2019.

- Boyapally, R., G. Pulivendala, S. Bale, and C. Godugu, *Niclosamide alleviates pulmonary fibrosis in vitro and in vivo by attenuation of epithelial-to-mesenchymal transition, matrix proteins & Wnt/beta-catenin signaling: A drug repurposing study.* Life Sci, 2019. **220**: p. 8-20.
- 145720. Cabrita, I., R. Benedetto, R. Schreiber, and K. Kunzelmann, Niclosamide repurposed for the1458treatment of inflammatory airway disease. JCl Insight, 2019. 4(15). 6693830
- Miner, K., K. Labitzke, B. Liu, P. Wang, K. Henckels, K. Gaida, R. Elliott, J.J. Chen, L. Liu, A. Leith, E. Trueblood, K. Hensley, X.Z. Xia, O. Homann, B. Bennett, M. Fiorino, J. Whoriskey, G. Yu, S.
 Escobar, M. Wong, T.L. Born, A. Budelsky, M. Comeau, D. Smith, J. Phillips, J.A. Johnston, J.G.
 McGivern, K. Weikl, D. Powers, K. Kunzelmann, D. Mohn, A. Hochheimer, and J.K. Sullivan, *Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A*Antagonists That Fully Bronchodilate Airways. (1663-9812 (Print)).
- 1465 22. Burock, S., S. Daum, U. Keilholz, K. Neumann, W. Walther, and U. Stein, *Phase II trial to*1466 *investigate the safety and efficacy of orally applied niclosamide in patients with metachronous*1467 *or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.*1468 BMC Cancer, 2018. **18**(1): p. 297. 5856000
- Burock, S., S. Daum, H. Trvðger, T.D. Kim, S. Krv⁰ger, D.T. Rieke, S. Ochsenreither, K. Welter, P.
 Herrmann, A. Sleegers, W. Walther, U. Keilholz, and U. Stein, *Niclosamide a new chemotherapy agent? Pharmacokinetics of the potential anticancer drug in a patient cohort of the NIKOLO trial.*Journal of Clinical Oncology, 2018. **36**(15_suppl): p. e14536-e14536.
- 1473 24. A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative
 1474 Proctosigmoiditis. 2018: Clinicaltrials.gov.

NIC for COVID Protocol 00000605 Selker PI

25. Guan, W.J., Z.Y. Ni, Y. Hu, W.H. Liang, C.Q. Ou, J.X. He, L. Liu, H. Shan, C.L. Lei, D.S.C. Hui, B. Du, 1475 1476 L.J. Li, G. Zeng, K.Y. Yuen, R.C. Chen, C.L. Tang, T. Wang, P.Y. Chen, J. Xiang, S.Y. Li, J.L. Wang, Z.J. 1477 Liang, Y.X. Peng, L. Wei, Y. Liu, Y.H. Hu, P. Peng, J.M. Wang, J.Y. Liu, Z. Chen, G. Li, Z.J. Zheng, S.Q. 1478 Qiu, J. Luo, C.J. Ye, S.Y. Zhu, and N.S. Zhong, *Clinical Characteristics of Coronavirus Disease 2019* in China. N Engl J Med, 2020. 7092819 1479 1480 26. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among 1481 Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. . MMWR Morb Mortal Wkly Rep, (69): p. 382-386. 1482 1483 27. Survey, N.H.I., Early release of selected estimates based on data from the 2018 National Health 1484 Interview Survey. US Department of Health and Human Services, CDC, 2020. 1485 28. Jin, X., J.S. Lian, J.H. Hu, J. Gao, L. Zheng, Y.M. Zhang, S.R. Hao, H.Y. Jia, H. Cai, X.L. Zhang, G.D. Yu, K.J. Xu, X.Y. Wang, J.Q. Gu, S.Y. Zhang, C.Y. Ye, C.L. Jin, Y.F. Lu, X. Yu, X.P. Yu, J.R. Huang, K.L. 1486 1487 Xu, Q. Ni, C.B. Yu, B. Zhu, Y.T. Li, J. Liu, H. Zhao, X. Zhang, L. Yu, Y.Z. Guo, J.W. Su, J.J. Tao, G.J. 1488 Lang, X.X. Wu, W.R. Wu, T.T. Qv, D.R. Xiang, P. Yi, D. Shi, Y. Chen, Y. Ren, Y.Q. Qiu, L.J. Li, J. Sheng, and Y. Yang, Epidemiological, clinical and virological characteristics of 74 cases of 1489 coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut, 2020. 1490 7133387 1491 1492 29. Hamming, I., W. Timens, M.L. Bulthuis, A.T. Lely, G. Navis, and H. van Goor, Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS 1493 pathogenesis. J Pathol, 2004. 203(2): p. 631-7. 7167720 1494 1495 30. Chang, Y.-W., T.-K. Yeh, K.-T. Lin, W.-C. Chen, H.-T. Yao, S.-J. Lan, Y.-S. Wu, H.-P. Hsieh, C.-M. 1496 Chen, and C.-T. Chen, Pharmacokinetics of Anti-SARS-CoV Agent Niclosamide and Its Analogs in Rats. Journal of Food and Drug Analysis, 2006. 14. 1497 31. Zhang, J.L., H.F. Si, X.F. Shang, X.K. Zhang, B. Li, X.Z. Zhou, and J.Y. Zhang, New life for an old 1498 1499 drug: In vitro and in vivo effects of the anthelmintic drug niclosamide against Toxoplasma gondii 1500 RH strain. Int J Parasitol Drugs Drug Resist, 2019. 9: p. 27-34. 6312869 1501 32. Domalaon, R., P.M. De Silva, A. Kumar, G.G. Zhanel, and F. Schweizer, *The Anthelmintic Drug* Niclosamide Synergizes with Colistin and Reverses Colistin Resistance in Gram-Negative Bacilli. 1502 Antimicrob Agents Chemother, 2019. 63(4). 6437516 1503 33. Tam, J., T. Hamza, B. Ma, K. Chen, G.L. Beilhartz, J. Ravel, H. Feng, and R.A. Melnyk, Host-1504 1505 targeted niclosamide inhibits C. difficile virulence and prevents disease in mice without disrupting the gut microbiota. Nat Commun, 2018. 9(1): p. 5233. 6286312 1506 1507 34. Farkouh, M.E., M. Domanski, G.D. Dangas, L.C. Godoy, M.J. Mack, F.S. Siami, T.H. Hamza, B. Shah, G.G. Stefanini, M.S. Sidhu, J.F. Tanguay, K. Ramanathan, S.K. Sharma, J. French, W. Hueb, 1508 1509 D.J. Cohen, and V. Fuster, Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. J Am Coll Cardiol, 2019. 73(6): p. 629-638. 1510 6839829 1511 1512 35. Hatamipour, M., M.R. Jaafari, A.A. Momtazi-Borojeni, M. Ramezani, and A. Sahebkar, 1513 Development, characterization and evaluation of in vivo anti-tumor activity of niclosamide 1514 nanoliposomes against colon carcinoma. Curr Mol Pharmacol, 2019.

1515 36. Hatamipour, M., M.R. Jaafari, A.A. Momtazi-Borojeni, M. Ramezani, and A. Sahebkar, 1516 Nanoliposomal Encapsulation Enhances In Vivo Anti-Tumor Activity of Niclosamide against Melanoma. Anticancer Agents Med Chem, 2019. 19(13): p. 1618-1626. 1517 1518 37. Huang C, wang Y, Li X, et al. (2020) Clinical features of patients infected with 2019 novel 1519 coronavirus in Wuhan, China. Lancet 395: 497-506. 38. Ding S, Lian TJ. (2020) Is SARS-CoV-2 Also an Enteric Pathogen With Potential Fecal– Oral 1520 Transmission? A COVID-19 Virological and Clinical Review. Gastroenterology. 5: 1-9. 1521 39. Lescure, Francois-Xavier et al. (2020) Clinical and virological data of the first cases of COVID-19 1522 1523 in Europe: a case series. The Lancet Infectious Diseases. 20(6):697 – 706. 1524 40. Luo, F., Luo, M., Rong, Q. et al. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. j. immunotherapy cancer 7, 1525 245 (2019). https://doi.org/10.1186/s40425-019-0733-7. 1526 41. Azzi L, Carcano G, Dalla Gasperina D, Sessa F, Maurino V, Baj A. Two cases of COVID-19 with 1527 positive salivary and negative pharyngeal or respiratory swabs at hospital discharge: A rising 1528 concern [published online ahead of print, 2020 Apr 25]. Oral Dis. 2020;10.1111/odi.13368. 1529 1530 doi:10.1111/odi.13368 1531 42. Wyllie, A.L., Fournier, J., Casanovas-Massana, A., Campbell, M., Tokuyama, M., Vijayakumar, P., 1532 Geng, B., Muenker, M.C., Moore, A.J., Vogels, C.B. and Petrone, M.E., 2020. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. Medrxiv. 1533 1534 1535

- 1 Statistical analysis plan -- Niclosamide for Patients with Mild to Moderate Disease
- 2 from Novel Coronavirus (COVID-19)
- 3 Clinicaltrials.gov NCT04399356
- 4 SAP version 1, July 13, 2021, based on protocol version 8.0, February 2021

5 SAP contributors

- 6 Ludovic Trinquart
- 7 Lori Lyn Price

8 Background and rationale

- 9
- 10 Therapeutic approaches are needed to improve outcomes in patients with COVID-19. Niclosamide is an
- 11 oral anthelminthic drug primarily used to treat parasitic infections. However niclosamide may have
- 12 broad clinical applications to treat diseases other than those caused by parasites. Niclosamide has
- 13 potent antiviral activity against single-stranded RNA viruses including coronaviruses. It was proposed as
- 14 an antiviral during the SARS outbreak in 2002. It was found to inhibit SARS coronavirus, SARS-CoV, in *in*
- 15 *vitro* studies and similarly structured RNA viruses (both *in vitro* and *in vivo*). Niclosamide has antiviral
- 16 properties for similarly structured pathogenic viruses, including Zika virus, adenovirus, dengue, and
- 17 chikungunya virus.
- 18 Because the drug is inexpensive and has few if any side effects, taking Niclosamide prophylactically
- 19 might help to prevent COVID-19 spreading. Even if this treatment does not completely eradicate
- 20 infection, niclosamide treatment may help to decrease viral load, thereby allowing the host immune
- 21 system to better combat the disease.

22 Objectives

- 23
- 24 Primary Objective: To evaluate the efficacy of niclosamide in shortening contagious period as
- 25 determined by time to viral clearance.
- Secondary Objectives: To evaluate the efficacy of niclosamide on symptoms and progression to severeCOVID-19.

28 Study Methods

- 29 Trial design
- 30 The trial is a single-center, randomized, parallel-group, placebo-controlled trial. Treatment allocation
- 31 was a 1:1 ratio. Patients were randomized to either niclosamide (2 grams orally once daily for 7 days) or
- 32 matched placebo control.
- 33 Randomization
- 34 The random allocation sequence was computer-generated by a biostatistician. Randomization was
- 35 stratified into three strata: Tufts lab and non-Tufts lab. We used blocking (block size 4). The random
- 36 allocation sequence was implemented into the Redcap Electronic Data Capture (EDC) system which
- 37 guaranteed concealment of the sequence until treatments were assigned.
- 38 Sample size
- 39 For the primary efficacy endpoint of respiratory virologic clearance at Day 3 measured by oropharyngeal
- 40 viral shedding, 40 participants in each group achieve 89.1% power to detect a difference between the
- 41 group proportions of 35%. We assumed that 50% and 15% of participants in the niclosamide and
- 42 placebo groups would have a negative test on Day 3. The calculation was under a two-sided Fisher's
- 43 Exact Test and a significance level of 0.05.
- 44 Framework
- 45 For all objectives, we test for superiority of niclosamide against placebo.
- 46 Statistical interim analyses and stopping guidance
- 47 We did not plan or perform any interim analyses.
- 48 The trial was closed to recruitment on June 22, 2021 due to the effective ending of the COVID-19
- 49 epidemic in Massachusetts resulting in lack of available candidates.

- 50 Timing of final analysis
- 51 Final analysis will take place in one stage, when every patient has reached 30-day follow-up and data for
- 52 the primary and secondary endpoints have been received and cleaned.
- 53 Timing of outcome assessments, including visit windows
- 54 Primary efficacy endpoint: respiratory viral clearance at Day 3.
- 55 Secondary efficacy endpoints
- Fecal viral clearance at Day 14.
- Reduction in viral shedding as measured by oropharyngeal swab on days, 3, 7, 10, 14.
- Reduction in fecal viral shedding as measured by fecal PCR on days, 3, 7, 10, 14 and 21.
- Progression to severe COVID.
- Resolution of symptoms (including but not limited to fever, cough, fatigue).

61 Statistical principles

- 62 Confidence intervals and P values
- All statistical tests will be 2-sided and will be performed using a 5% significance level. We will derive 95%
- 64 two-sided confidence intervals.
- 65 Adherence and protocol deviations
- 66 In this study, four pills are to be taken daily for 7 days. Compliance is assessed by the percentage of
- 67 subjects who have taken the scheduled number of pills:
- 68 % compliance = 100x (number of pills taken / 28 pills supposed to have been taken).
- 69 We will summarize compliance by randomization group: mean % compliance as well as number and
- 70 percentage of participants with more than 80% compliance (24 pills out of 28).
- 71 Similarly, we will assess compliance with oropharyngeal and fecal sampling.
- 72 Protocol deviations will be classified into:
- PCR > 3 days before randomization
- taking the first dose before the first telehealth visit
- missing at least 1 telehealth visit
- collecting at least one oropharyngeal sample outside of window (day 1, 3, 7, 10, 14 ±1 day)
- collecting at least one fecal sample outside of window (day, 1, 3, 7, 10, 14, 21 ±1 day)
- collecting less than 5 oropharyngeal samples
- collecting less than 6 fecal samples
- taking the wrong dose at least once
- taking the wrong dose at least once
- missing a dose at least once
- expected assessments not completed during at least one telehealth visit (e.g., physician disconnected)
- 84 Protocol deviations were classified prior to unblinding of treatment assignment. We will report detailed
- 85 protocol deviations per participant. We will summarize the number and percentage of participants with
- 86 protocol deviations by treatment group with details of type of deviation.
- 87 Analysis populations
- We will exclude participants who withdrew consent after randomization but before taking any sample orpill.
- 90 The intention-to-treat (ITT) population will include all randomized patients according to the treatment
- 91 they were randomized to receive.

- 92 The per-protocol population will a subset of the participants in the full analysis (ITT) set who took at
- 93 least 80% of study intervention.
- 94 The modified ITT population will include participants who took at least one pill, have a positive
- 95 oropharyngeal test result on Day 1 and have Day 3 oropharyngeal sample results available for analysis.
- 96 The safety population will include participants who took at least one pill.

97 Trial population

- 98 Screening, eligibility, recruitment, and withdrawal/follow-up
- 99 We will use a CONSORT flow diagram to summarize the number of participants who were:
- 100 assessed for eligibility at screening
- 101 eligible at screening
- 102 eligible and randomized
- 103 withdrew prior to received first dose
- 104 randomized and included in the primary analysis
- 105 The flow diagram will also show the numbers who were eligible but not randomized, who did not
- 106 receive the randomized allocation, who were lost to follow-up, who discontinued the intervention, and
- 107 we will describe the reasons.
- 108 Baseline patient characteristics
- 109 Participants will be described at the time of randomization with respect to age, sex, race/ethnicity,
- 110 COVID-19 symptoms, smoking, obesity/overweight, asthma, COPD, cancer, cerebrovascular disease,
- 111 CKD, cystic fibrosis, heart conditions, hypertension, immunocompromised state, liver disease, neurologic
- 112 conditions, pulmonary fibrosis, sickle cell disease, thalassemia, diabetes, both overall and separately for
- 113 the two randomization groups. We will summarize categorical data by numbers and percentages. We
- 114 will summarize continuous data by mean, SD (or median, Q1-Q3 if data are skewed). We will not
- 115 undertake tests of statistical significance. We will note the clinical importance of any imbalance.

116 Analysis

- 117 *Outcome definitions*
- 118 <u>Viral clearance</u>
- 119 Respiratory viral clearance is defined as the first day a participant's oropharyngeal sample result is
- 120 negative, provided that none of the subsequent oropharyngeal sample results are positive. In primary
- 121 analyses, we will use sample results (positive or negative) as returned by Diagnostic Solutions
- 122 Laboratory. We will use a similar definition for fecal viral clearance. We will calculate the time to
- 123 clearance since Day 1.
- 124 If a participant has several samples on the same day, we will consider the result to be positive if at least 125 one of the sample results is positive, and negative otherwise.
- 126 In table 1, we illustrate possible patterns of time to viral clearance and time post-viral clearance. We
- 127 illustrate samples available on days per protocol. But, according to our definition of clearance, time to
- 128 clearance and time post-clearance are identifiable even if samples taken on different days.
- 129 Table 1: Patterns of sample results and time to viral clearance

Day 1	Day 3	Day 7	Day 10	Day 14	Clearance	Time to	Time post-
					vs.	clearance	clearance
					censored		

+	+	+	-	-	1	10	4
-	-	-	-	-	1	1	13
-	+	-	+	+	0	14	0
-	+	-	-	-	1	7	7

131 In absence of deviations from protocol, we expect oropharyngeal sample results on 5 distinct days (day

132 1, 3, 7, 10, 14) and fecal sample on 6 distinct days (day 1, 3, 7, 10, 14, 21). Some participants may have

133 samples on less than 5 or 6 distinct days. We will identify the occurrence of viral clearance as defined

above based on available samples. If clearance is not observed, we will censor participants at their last

available sample. In Table 2, we illustrate possible patterns of non-available sample results.

136 Table 2: Patterns of days without sample result available and time to viral clearance

Day 1	Day 3	Day 7	Day 10	Day 14	Clearance	Time to	Time post-
					vs.	clearance	clearance
					censored		
+	+	NA	-	-	1	10	4
-	-	-	NA	NA	1	1	6
-	+	-	+	NA	0	10	0
-	+	NA	-	-	1	10	4

137 NA: not available.

138 Analysis methods

139 Primary analysis

140 The primary endpoint is viral clearance in respiratory samples at day 3. The primary analysis will be

141 based on the ITT population (i.e., all randomized participants). We will estimate the cumulative

142 probability of being in clearance in each randomization group by using the Kaplan-Meier estimator. We

143 will compare the cumulative probability of clearance at day 3 between the two groups by using a chi-

square test based on a log $(-\log(\cdot))$ transformation for the survival function.[Klein et al. Statist. Med.

145 2007; 26:4505-4519].

$$\chi^{2} = \frac{\left\{ \log\left(-\log\left(\hat{S}_{1}(t)\right)\right) - \log\left(-\log\left(\hat{S}_{0}(t)\right)\right)\right\}^{2}}{\frac{\hat{\sigma}_{1}(t)^{2}}{\log\left(\hat{S}_{1}(t)\right)^{2}} + \frac{\hat{\sigma}_{0}(t)^{2}}{\log\left(\hat{S}_{0}(t)\right)^{2}}}$$

- 146 Under the null hypothesis of no difference in probability of being in clearance between the two groups,
- 147 the statistic of test is asymptotically χ_1^2 -distributed. We will provide the between-group difference in
- probability of viral clearance at day 3 and the associated 95% confidence interval based on the cloglog transformation of the survival function.
- 150 Secondary analyses
- 151 In secondary analyses,

- We will compare the respiratory clearance probability functions from day 1 to 14 between the two groups by using a log-rank test.
- We will calculate the area under each respiratory clearance-free probability curve which gives
 the mean time to viral clearance up to day 14. We will estimate the mean difference in time
 post-viral clearance between groups and the associated 95% confidence interval.
- We will compare how the proportion of negative oropharyngeal sample results evolved over
 time between treatment groups by using random-intercepts logistic regression models for
 longitudinal binary outcome data.
- 160 4) We will repeat the primary analysis for fecal viral clearance at day 14.
- 161 5) We will repeat the secondary analyses 1)-3) above for fecal viral clearance.
- 6) We will repeat the primary and secondary analysis by considering the combined oropharyngeal
 and/or fecal sample results. If both types of samples are available on a given day, we will
 consider the result to be positive if at least one of the sample results is positive, and negative
 otherwise. If only one type of sample is available on a given day and it is positive (respectively
 negative), the result will be positive (negative) for that day.
- 167 7) We will compare the proportion of participants who progressed to severe COVID disease168 between groups.
- 8) We will compare the proportions of participants free of symptoms. We will include participants
 who reported symptoms on Day 1 and we will assess the time to symptom resolution (symptom no longer reported). We will analyze 8 symptom categories described in Table 3.
 - 9) We will repeat the primary and secondary analyses for viral clearance in the mITT population.
- 173 10) We will repeat the primary and secondary analyses for viral clearance in the per protocol174 population.
- 175

176 <u>Subgroup analyses</u>

177 We pre-specified subgroup analyses of viral clearance and symptom resolution according to BMI (<25

178 kg/m² vs. \geq 25 kg/m²) and according to diabetes.

179 <u>Exploratory analyses</u>

- In exploratory analyses, we will repeat the primary and secondary analyses of viral clearance by
 calculating the time to viral clearance from the confirmatory PCR before randomization.
- 182 Moreover, in an analysis blinded to random allocation, we will analyze the trajectories of oropharyngeal
- and fecal sample results. In particular, we will identify participants with a negative test result followed
- 184 by at least one positive test result (as defined by the DSL COVID-19 Assay); we will examine the Ct values
- 185 of the positive test results following a negative test result. We will repeat the primary and secondary
- analyses by considering alternative thresholds to define a positive result, based on the blinded review ofdata.
- 188 We also will perform longitudinal analyses to assess the between-group difference in gene expression
- 189 over time. For each participant and each sample, we will calculate the difference in expression (in terms
- 190 of quantification cycle) between the target gene (SARS-CoV-2 specific nucleocapsid N1; panspecific CoV
- 191 nucleocapsid N3; or SARS-CoV-2 spike) and a reference gene (RNase P): ΔCq= Cq(target
- 192 gene)–Cq(reference gene). We will create spaghetti plots in each randomization group with lowess
- 193 smoother curve superimposed. We will create heatmaps of Δ Cq values scaled to the mean and standard
- deviation within each participant. We will use linear mixed models, including a term for the group, a
- 195 term for time, and group x time interaction term and a subject-level random intercept, to compare the
- 196 trajectories in normalized expression between groups over time.

- 197 Data will include a number of non-detects, i.e. reactions lacking a Cq value. Missing Cq value can
- 198 correspond to a true Cq value above the Cq threshold. Alternatively it can correspond to zero expression
- 199 (no amplification above the Cq threshold). Or it can correspond to a failure to detect a true Cq value
- below the Cq threshold. We will account for non-detects by setting undetermined Cq values at 40. In
- sensitivity analyses, we will account for non-detects by using hot deck imputation.
- 202 We will also consider the following modified ITT analyses of viral clearance:
- 203 for the analysis based on oropharyngeal samples, fecal samples, and both types, we will include
- participants who took at least one pill, have a positive test result at any time during the trial and haveDay 3 sample results available for analysis.
- for the analysis based on fecal samples, we will include participants who took at least one pill, have a
 positive oropharyngeal test result and have Day 3 fecal sample results available for analysis.
- 208 Missing data
- 209 For the longitudinal analyses, we will perform sensitivity analyses by imputing data according to
- 210 sequential multiple imputation
- 211 Harms
- 212 The number (and percentage) of patients experiencing each adverse event will be presented, both for
- 213 the overall safety population and in each randomization group. We will not perform statistical testing.
- 214 We will assess the clinical significance of the differences. Adverse events will include abdominal pain,
- 215 congestion or runny nose, cough, diarrhea, dizziness, dyspnea, fatigue, fever or chills, headaches,
- 216 hypoxia, loss of appetite, muscle or body aches, nausea, new loss of taste or smell, pruritus, shortness of
- 217 breath/difficulty breathing, skin rash, sore throat, vomiting, and other.
- 218 Statistical software
- 219 The analysis will be carried out by using SAS and R.
- 220
- 221

222 Table 3: Classification of symptoms into 8 categories

1.Central nervous system
Dizziness
Fatigue
Headache
2.Upper gastrointestinal
Appetite change
Nausea
Vomiting
3.Lower gastrointestinal
Abdominal pain
Diarrhea
4.Ear, nose, throat
Sore throat
Congestion
Loss of taste/smell
5.Respiratory/Pulmonary
Cough
Dyspnea/Shortness of breath
Нурохіа
6.Musculoskeletal
Muscle aches
Dermatologic
Rash
Pruritus
7.Systemic
Fever/Chills
8.Other